

Easily Available, Amphiphilic Diiron Cyclopentadienyl Complexes Exhibit in Vitro Anticancer Activity in 2D and 3D Human Cancer Cells through Redox Modulation Triggered by CO Release

Lorenzo Biancalana,^[a] Michele De Franco,^[b] Gianluca Ciancaleoni,^[a] Stefano Zacchini,^[c] Guido Pampaloni,^[a] Valentina Gandin,^{*,[b]} and Fabio Marchetti^{*,[a]}

Abstract: A straightforward two-step procedure via single CO removal allows the conversion of commercial $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ into a range of amphiphilic and robust ionic complexes based on a hybrid aminocarbyne/iminium ligand, $[\text{Fe}_2\text{Cp}_2(\text{CO})_3\{\text{CN}-(\text{R})(\text{R}')\}]\text{X}$ (R, R' = alkyl or aryl; X = CF_3SO_3 or BF_4), on up to multigram scales. Their physicochemical properties can be modulated by an appropriate choice of N-substituents and counteranion. Tested against a panel of human cancer cell lines, the complexes were shown to possess promising antiproliferative activity and to circumvent multidrug resist-

ance. Interestingly, most derivatives also retained a significant cytotoxic activity against human cancer 3D cell cultures. Among them, the complex with R = 4- $\text{C}_6\text{H}_4\text{OMe}$ and R' = Me emerged as the best performer of the series, being on average about six times more active against cancer cells than a noncancerous cell line, and displayed IC_{50} values comparable to those of cisplatin in 3D cell cultures. Mechanistic studies revealed the ability of the complexes to release carbon monoxide and to act as oxidative stress inducers in cancer cells.

Introduction

Transition metal complexes have unique characteristics which constitute an indispensable potential in medicinal chemistry, such as the availability of adjacent oxidation states of the metal enabling redox reactions, the reactivity of the coordinated organic fragments addressed by the metal centre, and a broad range of possible geometries, stereochemical configurations and kinetic behaviours.^[1] In the last century, the serendipitous discovery of the cytotoxic properties of cisplatin preceded the

introduction of few platinum complexes in clinical treatments against various types of cancer.^[2] Then, the severe side effects caused by limited selectivity, platinum toxicity and resistance issues^[3] have fuelled an intense research for alternative drugs based on other transition metals.^[4] In principle, iron is a convenient choice, since it is a bioavailable element and nontoxic in many forms,^[5] moreover, its earth abundancy has made several cost-effective compounds available to the researchers for the exploration of the reactivity and the consequent development of new structural motifs. A variety of mono-iron compounds has been investigated for the anticancer potential,^[6,7] and substituted ferrocenes (ferrocifens) have been regarded as promising drug candidates.^[8] The feasible Fe^{+II} to Fe^{+III} oxidation in the physiological environment and the conjugation of suitable organic moieties to the robust sandwich scaffold are responsible for a considerable activity, which is basically related to the production of damaging metabolites within cancer cells.^[9]

Following the findings on ferrocifens, some *half-sandwich* compounds, both neutral-charged (Figure 1, structure I)^[10] and cationic (structures II–III),^[10c,11] were recently assessed for their cytotoxicity against various cancer cell lines, which might be enhanced by the synergic effect provided by the release of the carbon monoxide co-ligands.^[12] A critical aspect is that, in general, ferrocifens and other organo-iron compounds possess a poor solubility in physiological environments,^[13] resulting in serious drawbacks in the view of clinical applications.^[14] In this overall scenario, the medicinal potential of diiron bis-cyclopentadienyl compounds was unexplored until 2019. The commercial dimer $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ (Cp = $\eta^5\text{-C}_5\text{H}_5$) represents an inexpensive and convenient entry into the chemistry of diiron

[a] Dr. L. Biancalana, Prof. G. Ciancaleoni, Prof. G. Pampaloni, Prof. F. Marchetti
Department of Chemistry and Industrial Chemistry
University of Pisa
Via G. Moruzzi 13, I-56124 Pisa (Italy)
E-mail: fabio.marchetti1974@unipi.it
Homepage: https://people.unipi.it/fabio_marchetti1974/

[b] Dr. M. De Franco, Prof. V. Gandin
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Via F. Marzolo 5, I-35131 Padova (Italy)
E-mail: valentina.gandin@unipd.it
Homepage: <https://www.dsfarm.unipd.it/valentina-gandin>

[c] Prof. S. Zacchini
Department of Industrial Chemistry "Toso Montanari"
University of Bologna
Viale Risorgimento 4, I-40136 Bologna (Italy)

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/chem.202101048>

© 2021 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.




Figure 1. Structures of cyclopentadienyl iron complexes that show anticancer activity (plus year of publication). I) L = PPh₂(alkyl), Y = C(O)Me (2020);^[10a] L = CO, Y = Cl, Br, I, NCS, SCN (2016);^[10b] L = PPh₃ or related ring-substituted molecule, Y = I (2017).^[10c] II) R = Ph, 4-C₆H₄CO₂H or 4-C₆H₄F, R' = 4-C₆H₄NH₂, X = PF₆ (2017);^[10d] R = Ph, R' = aryl or vinyl, X = CF₃SO₃ (2020).^[11c] III) L = imidazole or N-substituted imidazole, X = CF₃SO₃ (2013);^[11d] L = carbohydrate-substituted nitrile, X = PF₆ (2015);^[11a] L = N-heteroaromatic nitrile, X = PF₆ or CF₃SO₃ (2014).^[11b] IV) R = Me, CH₂Ph or 2,6-C₆H₃Me₂ (Xyl), R' = alkyl, aryl, pyridyl, or thiophenyl, Y = H, Ph or S/Se group (2019, 2020).^[17a,b]

compounds, and a plethora of organometallic motifs has been constructed on a bridging coordination site, exploiting the cooperativity of the two metal centres.^[15] Some of us reported a preliminary evaluation of the anticancer activity of complexes based on the {Fe₂Cp₂(CO)_x} core (x = 2 or 3),^[16] and especially those ones with a bridging vinyliminium ligand (Figure 1, structure IV) displayed interesting preliminary cytotoxicity profiles.^[17]

Here, we show that a general and straightforward two-step synthetic procedure (reproducible in multigram scales) allows to access a family of compounds showing a promising antiproliferative activity against 2D and 3D human cancer cell systems. Remarkably, 3D cell culture studies constitute an excellent base for more advanced in vivo cancer research, surpassing the traditional assays on monolayer cultures,^[18] indeed, 2D models provide limited predictivity for drug testing, while 3D models promise to bridge the gap between traditional 2D cell cultures and in vivo animal models.^[19]

To the best of our knowledge, the present 3D investigation is one of the first ones ever reported on iron compounds. The proposed diiron complexes combine within a cationic structure two Cp rings, three carbonyls and a variable bridging amino-carbyne ligand, the latter tuning the water solubility, the lipophilicity and the activity. Several experiments aimed to clarify the mechanism of action of the complexes will be discussed.

Results and Discussion

Synthesis and characterization of diiron complexes and structural studies

The known complexes 1A–H were prepared by the thermal substitution reaction of the corresponding isocyanides with a

slight molar excess of [Fe₂Cp₂(CO)₄] in acetonitrile.^[20] The final reaction mixtures were dried, and the crude residues were dissolved in dichloromethane or acetonitrile and treated with a range of alkylating agents under optimized conditions, to afford the corresponding products [2–5]⁺ (Table 1). The products were purified by alumina chromatography (see the Experimental Sections for details), and finally isolated in good to quantitative yields in a 300 mg to 10 g scale. Deliquescent [2B]CF₃SO₃ was converted into the less moisture-sensitive tetrafluoroborate salt by repeated treatment with NaBF₄ in water followed by CH₂Cl₂ extraction. A minor amount of [2C]Cl was isolated from the chromatography of [2C]CF₃SO₃, as a result of triflate/chloride exchange during the chromatographic purification, due to chloride impurities in commercial alumina; then, [2C]Cl was reliably obtained from [2C]CF₃SO₃ using a cation exchange resin. In order to ensure the solid-state stability of the compounds, the light-sensitive anions of [3F] and [5H]Br were exchanged by metathesis with AgCF₃SO₃ in MeCN. In summary, Table 1 shows a general approach to obtain easily accessible ionic diiron complexes with variable substituents on the bridging hydrocarbyl ligand and counter anions, based on the choice of the isocyanide and the alkylating agent, thus offering wide opportunity for tuning the physicochemical properties (Scheme S1 in the Supporting Information). The cations [2A–C]⁺, [4G]⁺ and [5H]⁺ are unprecedented in the literature, while the others were previously isolated as [2D–F]CF₃SO₃,^[21,22] [3F]⁺^[23] and [3G]CF₃SO₃,^[20] however, the salts [3G] and [3F]CF₃SO₃ are novel and an optimized synthesis for [3F] is supplied here. The incorporation of the indolyl moiety in [2A]CF₃SO₃ is of some relevance, because many indole derivatives have been reported as potent anticancer agents, and some of them have been approved by FDA for clinical treatment.^[24] On the other hand, the introduction of the highly polar diethylphosphonato group in [2B]BF₄ is functional to enhance the water solubility.^[25]

New compounds were fully characterized by elemental analysis, IR and multinuclear NMR spectroscopy. In addition, the

Table 1. Two-step preparation of cationic diiron bis-cyclopentadienyl complexes with bridging aminocarbyne ligands. Experimental conditions for the second step: [2A–F]⁺, CH₂Cl₂, room temperature; [3F]⁺, MeCN, RT; [3G]⁺ and [5H]⁺, MeCN, reflux; [4G]⁺, MeCN, 0 °C. *Not isolated.

R	R'X	Product	Counterion
1H-indol-6-yl	CH ₃ SO ₃ CF ₃	[2A] ⁺	[2A] ⁺
CH ₂ P(O)(OEt) ₂	CH ₃ SO ₃ CF ₃	[2B] ⁺	[2B] ⁺
Cy = C ₆ H ₁₁	CH ₃ SO ₃ CF ₃	[2C] ⁺	[2C] ⁺
4-C ₆ H ₄ OMe	CH ₃ SO ₃ CF ₃	[2D] ⁺	[2D] ⁺
Xyl = 2,6-C ₆ H ₃ Me ₂	CH ₃ SO ₃ CF ₃	[2E] ⁺	[2E] ⁺
Me	CH ₃ SO ₃ CF ₃	[2F] ⁺	[2F] ⁺
	CH ₂ =CHCH ₂ I	[3F] ⁺	[3F] ⁺
2-naphthyl	CH ₃ I	[3G] ⁺	[3G] ⁺
	[Et ₃ O]BF ₄	[4G] ⁺	[4G] ⁺
CH ₂ Ph	PhCH ₂ Br	[5H] ⁺	[5H] ⁺

structures of $[2A]CF_3SO_3$, $[2C]CF_3SO_3$, $[2C]Cl$ and $[2D]CF_3SO_3$ were confirmed by single crystal X-ray diffraction. Relevant bonding parameters are comparatively compiled in Table 2, and a view of the cations are shown in Figure 2. The structure of the cations consists of a typical *cis*- $\{Fe_2Cp_2(CO)_2\}$ core, connected to a further CO and an aminocarbene group occupying the two bridging sites. Along this series of complexes, the C(4)–N(1) distance does not significantly vary, indicating a substantial double-bond character which accounts for the complementary description of the bridging ligand as iminium (see below).

The bonding description of $\{\mu-CNR(R')\}$ ligands in dimetal complexes is not clearly defined in the literature, therefore we performed a DFT study to shed light on this point. The representative structure of $[2C]^+$ was calculated and compared to that of the parent compound *cis*-1C with a bridging cyclohexyl-isocyanide ligand (CNCy). DFT-optimized structures and relevant bonding parameters are reported in Table S1 and

Figure S1. In 1C, the $(\mu-C)-N$ Mayer bond order (b.o.)^[26] is 2.0 and the bond distance is 1.233 Å, in agreement with the X-ray data available for related systems $[(\mu-C)-N = 1.26(3) \text{ Å for CNCiPr instead of CNCy}]$.^[27] The b.o. of $(\mu-C)-N$ lowers to 1.58 upon methylation of the isocyanide moiety leading to $[2C]^+$. The nature of the nitrogen substituents has a negligible influence, and for instance the corresponding b.o. is 1.54 in the case of $[2A]^+$, the related bond length being consistent with the crystallographic characterization of $[2A]CF_3SO_3$ [1.300 vs. 1.289(7) Å; Table 2]. These theoretical results strongly support the description of the bridging N-containing ligand in the cationic complexes $[2-5]^+$ as an almost perfect aminocarbene-iminium hybrid structure (Figure 3).

Then, in order to clarify the possible effect of the net ionic charge of the complex, we also synthesized and characterized the novel neutral derivative $[Fe_2Cp_2Cl(CO)(\mu-CO)(\mu-CNMe(Cy))]$, 6 (see Experimental Section). Based on a comparison of the 1H

Table 2. Selected bond lengths [Å] and angles [°] for $[2A]^+$, $[2C]^+$, and $[2D]^+$.

	$[2A]^+$	$[2C]^+$ ^(a)	$[2C]^+$ ^(b)	$[2D]^+$
Fe(1)–Fe(2)	2.5136(11)	2.509(3)	2.5152(15)	2.5161(10)
Fe(1)–C(1)	1.760(6)	1.765(16)	1.776(7)	1.774(6)
Fe(2)–C(2)	1.782(6)	1.760(16)	1.754(8)	1.762(6)
Fe(1)–C(3)	1.954(6)	1.924(16)	1.915(8)	1.935(5)
Fe(2)–C(3)	1.944(6)	1.965(16)	1.962(7)	1.934(5)
Fe(1)–C(4)	1.874(6)	1.881(14)	1.883(8)	1.870(5)
Fe(2)–C(4)	1.870(6)	1.873(15)	1.888(8)	1.866(5)
C(1)–O(1)	1.137(7)	1.119(17)	1.139(9)	1.139(6)
C(2)–O(2)	1.131(7)	1.119(17)	1.147(10)	1.148(7)
C(3)–O(3)	1.155(7)	1.150(18)	1.172(9)	1.161(6)
C(4)–N(1)	1.289(7)	1.291(18)	1.274(10)	1.287(6)
Fe(1)–C(3)–Fe(2)	80.3(2)	80.3(6)	80.9(3)	81.1(2)
Fe(1)–C(4)–Fe(2)	84.3(2)	83.9(6)	83.7(3)	84.7(2)
Fe(1)–C(1)–O(1)	177.9(6)	178.9(14)	178.5(7)	175.6(5)
Fe(1)–C(2)–O(2)	177.8(6)	179.6(15)	179.5(8)	176.3(5)
C(4)–N(1)–C(5)	122.2(5)	122.6(12)	122.5(7)	123.4(4)
C(4)–N(1)–C(6)	124.1(5)	121.0(12)	121.4(6)	120.9(4)
C(5)–N(1)–C(6)	113.7(4)	116.3(11)	116.0(6)	115.5(4)

(a) As $[2C]CF_3SO_3$, (b) As $[2C]Cl$.




Figure 2. Molecular structures of $[2A]^+$, $[2C]^+$ and $[2D]^+$ (triflate salts). Displacement ellipsoids are at the 30% probability level. H-atoms have been omitted for clarity.




Figure 3. Resonance structures for the bridging hydrocarbonyl ligand in the diiron complexes [2–5]⁺ and 6. Structures I and II: aminocarbyne; structure III: iminium.

NMR and IR spectra with data available in the literature for similar compounds,^[28] 6 exists in CDCl₃ solution as a nearly equimolar mixture of two isomers, maintaining the *cis*-geometry of the Cp ligands (as ascertained by ¹H NOE experiments, Figure S32) and differing in the orientation of the *N*-substituents with respect to the chloride (*E/Z* isomers). This feature suggests that the (μ-C)–N bond in the neutral 6 still holds a substantial double bond character. The X-ray structure of the *E* isomer was determined and is shown in Figure S2, although the low quality of the crystals prevents a detailed discussion of bonding parameters.

In agreement with the NMR evidence, DFT outcomes indicate that 6^Z (*Z* isomer) and 6^E (*E* isomer) are practically isoenergetic, the latter being only 0.2 kcal mol^{−1} more stable than the former (Figure S1). In both *E/Z* isomers, the bridging {CN(Me)(Cy)} group resembles that in [2C]⁺, with only a slight decrease of the (μ-C)–N bond order (from 1.58 to 1.52). It is interesting to note that the bond length of the bridging carbonyl in 6 is very close to that in 1C (1.187 vs. 1.188 Å), highlighting that the isocyanide/CO and aminocarbyne/Cl combinations supply very similar electron densities for back-donation to the diiron framework.^[29]

Salient spectroscopic features of all complexes are summarized in Table S2, and NMR and IR spectra are supplied in Figures S3–S32. In the IR spectra (CH₂Cl₂ solution), the vibrations due to the terminal carbonyl ligands occur in the ranges 2018–2028 (anti-symmetric stretching) and 1985–1996 cm^{−1} (symmetric stretching), while the band related to the bridging carbonyl is found at 1833–1853 cm^{−1}. Moreover, the absorption attributed to the carbyne-N bond falls in between 1530 to 1602 cm^{−1}, the higher values being associated to the *N*-substituents with higher electron-donor ability. The ¹H and ¹³C NMR spectra (recorded in CDCl₃, CD₃CN or [D₆]DMSO) display one set of resonances, ascribable to a single isomeric form featuring the Cp ligands in mutual *cis* position, as found in the X-ray structures and confirmed by ¹H NOE experiments in the case of [4G]⁺ (Figure S27). Two resonances for the Cp and terminal CO ligands are distinguishable in the unsymmetrical complexes, due to hampered rotation around the partially double C–N bond (see above); accordingly, such resonances coincide in the complexes [2F]⁺ and [5H]⁺, displaying two identical N groups. In the ¹³C NMR spectra, the bridging {CN} unit is detected at low fields (i.e., around 320 ppm), as it is typical for bridging aminocarbynes.^[20,30] Compound [2B]⁺ features a ³¹P NMR

resonance at 17 ppm for the phosphonato group, and the ¹³C signal for the carbyne appears as a doublet (³J_{CP} ca. 6 Hz).

Small differences between the spectroscopic data of [2C] CF₃SO₃ and [2C]Cl in chlorinated solvents are ascribable to the presence of ion pairs (or higher aggregates);^[31] otherwise, the two compounds display superimposable ¹H NMR spectra in protic polar solvents (D₂O and CD₃OD), where ion pairs are practically absent.^[32]

Solubility, partition coefficient, stability in aqueous media and interaction with a model protein

A detailed study on the behaviour of a selection of the diiron complexes in aqueous media was undertaken. Experimental procedures are provided in the Experimental Section and in the Supporting Information, with data collected in Tables 3, S3 and S4. The D₂O solubility of the compounds was assessed by ¹H NMR, ranging from sub-millimolar to 0.15 M in the case of [2C] Cl. The octanol/water partition coefficients (log *P*_{ow}) were measured by a UV/Vis method and fall in between 0 and −1, reflecting an amphiphilic or slightly hydrophilic character. An exception is represented by [2B]BF₄, wherein the marked hydrophilicity imparted by the diethylphosphonato does not appear sufficiently balanced (log *P*_{ow} < −1.5). Conversely, those complexes with aromatic groups (i.e., 1*H*-indol-6-yl, 2-naphthyl and bis-benzyl in [2A]⁺, [3G]⁺, [4G]⁺ and [5H]⁺) are less soluble in water and display increased affinity for *n*-octanol (log *P*_{ow} ≈ 0). The diiron compounds are inert in aqueous solution at room temperature, and undergo a slow degradation at 37 °C. Under such conditions, a variable amount (50 to 86%; Table S3) of the starting material was detected by ¹H NMR in D₂O or D₂O/CD₃OD mixtures after 72 h.^[33] During this time, the precipitation of a brown solid was observed, which in one case (from a [2C] CF₃SO₃ solution) was separated and identified as γ-Fe₂O₃ by Raman analysis. In addition, headspace GC analyses performed on 5% MeOH aqueous solutions of the compounds maintained at 37 °C allowed the identification and quantitation of the carbon monoxide released over a 48 h period (Table S4). These facts indicate that the thermal degradation process in aqueous

Table 3. Solubility in D₂O (21 °C) and octanol/water partition coefficient (log *P*_{ow}) for diiron compounds.

Compound	Solubility [mol L ^{−1}]	Log <i>P</i> _{ow}
[2A]CF ₃ SO ₃	ca. 3 · 10 ^{−4} M	0.0 ± 0.1
[2B]BF ₄	5.2 · 10 ^{−2} M	≤ −1.5
[2C]CF ₃ SO ₃	6.2 · 10 ^{−3} M	−0.46 ± 0.02
[2C]Cl	1.5 · 10 ^{−1} M	−1.1 ± 0.08
[2D]CF ₃ SO ₃	4.1 · 10 ^{−3} M	−0.25 ± 0.04
[2E]CF ₃ SO ₃ ^[b]	1.4 · 10 ^{−3} M	−0.27 ± 0.04
[2F]CF ₃ SO ₃ ^[b]	3.2 · 10 ^{−3} M	−0.9 ± 0.1
[3F]CF ₃ SO ₃	3.4 · 10 ^{−3} M	−1.01 ± 0.02
[3G]CF ₃ SO ₃ ^[b]	not soluble ^[a]	0.29 ± 0.03
[4G]BF ₄	not soluble ^[a]	0.1 ± 0.1
[5H]CF ₃ SO ₃	6 · 10 ^{−4} M	0.2 ± 0.02

[a] Solubility below the lowest value of quantitation (ca. 3 × 10^{−4} M). [b] Data taken from ref. 16a.

solution leads to the progressive disassembly of the organo-metallic scaffold.^[16] The presumed, controlled release of the iron centres (converted to iron oxide, see above) and carbon monoxide are two aspects that deserve attention with reference to the biological activity: note that the decay of ferrocene drug candidates into Fe^{II} ions was previously associated to their cytotoxicity,^[34] while the activity of various iron carbonyl complexes was correlated to CO dissociation in the physiological media.^[35]

Next, the stability of the diiron compounds in a cell culture medium (DMEM) solution at 37 °C, over a shorter time range (24 h), was assessed by ¹H NMR. Notably, a considerable fraction (70–88 %; Table S3) of the starting material was detected at the end of the experiment, with a limited formation of an orange-brown precipitate analogous to that described above.

To gain insights into the reactivity of the diiron compounds with possible biomolecular targets, we selected lysozyme, a small model protein often used to test interactions with metal compounds.^[36] Following 24 h incubation at 37 °C, diiron compounds/lysozyme solutions (2:1 molar ratio) in ammonium acetate were filtered and analysed by ESI-MS. In all cases, the original organometallic cation was identified as the major Fe-containing compound in solution (Figures S33–S40). Concerning the protein scaffold, the only identified adduct from the interaction with [2–3]⁺ was the methylated derivative, which was also checked by HPLC separation (Figure S41). The expected diiron counterparts, that is, 1A–H, could not be detected possibly due to their water insolubility. The [lysozyme + Me⁺] to [lysozyme] ratios, calculated on extracted ion

chromatograms after protein peak reconstruction, are reported in Table 4. Compounds lacking *N*-methyl groups (i.e., [4G]⁺ and [5H]⁺) did not react with lysozyme. Methylation is a common post-translational modification of protein/enzymes (methyltransferase enzymes) but it has also been observed as a result of the interaction of proteins with various electrophiles.^[37]

Cytotoxic activity in 2D cell cultures

The diiron complexes [2A]⁺, [2C–E]⁺, [3F–G]⁺, [5H]⁺ (as CF₃SO₃ salts) and [2B]⁺, [4G]⁺ (as BF₄ salts) were tested for their cytotoxic potential by means of the MTT assay, as reported in the Experimental Section. The most convenient counter anion in terms of preparation and handling/storage was chosen in each case; in particular, [2C]CF₃SO₃ was included in the study, while [2C]Cl was excluded, being highly moisture sensitive and thus affecting the accuracy of the weighting operation. The in-house human cancer cell line panel contains examples of ovarian (2008), colon (HCT-15), pancreatic (PSN-1), and breast (MCF-7) cancers as well as of melanoma (A375). Cisplatin was used as a reference and tested under the same experimental conditions. The cytotoxicity parameters, expressed in terms of IC₅₀ obtained after 72 h of exposure, are listed in Table 5. In addition, the cytotoxicity was also evaluated for shorter time of exposure (24 h) towards PSN-1 cancer cells (Table S5). Data analysis reveals that the cytotoxic activity showed by tested complexes is time- and dose-dependent. In particular, the highly hydrophilic complexes [2B]BF₄ and [3F]CF₃SO₃ did not impact cell viability (average IC₅₀ values were over 200 or 100 μM for all tested cell lines), whereas the other compounds elicited IC₅₀ values in the micromolar range. Despite all cytotoxic complexes showed an average in vitro antitumor potential lower than that of cisplatin, [2C]CF₃SO₃ and [2D]CF₃SO₃ proved to be the most effective derivatives, with average IC₅₀ values of 17.4 and 16.6 μM (72 h time trials), and showed a similar pattern of response over the five tested cell lines. In particular, [2D]CF₃SO₃ exhibits a comparable activity with respect to cisplatin against HCT-15, PSN-1 and MCF-7 cells.

As one of the main drawbacks of chemotherapeutics is the toxic effect toward noncancerous cells, we measured the

Table 4. Methylation ratio (%) upon lysozyme interaction with the diiron compounds (1:2 molar ratio, 24 h, 37 °C), as determined by ESI-MS measurements.

Compound	% Lysozyme methylation (alkylation) ^[a]	Compound	% Lysozyme methylation (alkylation) ^[a]
[2A]CF ₃ SO ₃	45 %	[2F]CF ₃ SO ₃	35 %
[2B]BF ₄	49 %	[3F]CF ₃ SO ₃	47 %
[2C]CF ₃ SO ₃	50 %	[4G]BF ₄	0 % ^[b]
[2D]CF ₃ SO ₃	31 %	[5H]CF ₃ SO ₃	0 % ^[b]
[2E]CF ₃ SO ₃	59 %	Blank exp	0 % ^[b]

[a] Calculated by the relative peak integrals for flow injection MS analysis.
[b] No other protein MS peak beside that of lysozyme was observed.

Table 5. In vitro antitumor activity of diiron complexes in 2D cell cultures. Cells (3–8 × 10³ mL⁻¹) were treated for 72 h with increasing concentrations of the tested compounds. The cytotoxicity was assessed by the MTT test. IC₅₀ values were calculated by a four-parameter logistic model 4-PL (*P* < 0.05). In brackets RF=IC₅₀ (resistant cells)/IC₅₀ (wild-type cells) for MCF-7 cells. SI = selectivity index (see main text).

Compound	IC ₅₀ (μM) ± SD 2008	HCT-15	A375	PSN-1	MCF-7	MCF-7 ADR	HEK293	SI
[2A]CF ₃ SO ₃	55.5 ± 4.8	69.5 ± 6.7	50.8 ± 6.1	54.3 ± 6.2	63.2 ± 5.5	84.5 ± 8.5 (1.3)	135.5 ± 6.4	2.3
[2B]BF ₄	> 100	> 100	> 100	> 100	> 100	> 100	> 100	–
[2C]CF ₃ SO ₃	28.4 ± 5.4	9.2 ± 1.8	16.8 ± 2.1	15.3 ± 2.7	17.3 ± 3.3	23.3 ± 4.1 (1.3)	62.5 ± 4.9	3.6
[2D]CF ₃ SO ₃	21.3 ± 3.1	15.6 ± 3.5	15.5 ± 2.6	16.2 ± 2.9	14.3 ± 2.6	22.6 ± 4.2 (1.6)	94.3 ± 6.1	5.6
[2E]CF ₃ SO ₃	38.8 ± 4.5	37.3 ± 3.5	34.6 ± 4.0	41.7 ± 6.3	44.7 ± 5.5	66.9 ± 5.2 (1.5)	96.6 ± 2.9	2.4
[3F]CF ₃ SO ₃	> 100	> 100	> 100	> 100	> 100	> 100	> 100	–
[3G]CF ₃ SO ₃	36.6 ± 3.4	24.6 ± 2.9	25.2 ± 3.3	26.3 ± 2.8	20.7 ± 3.0	30.5 ± 6.7 (1.5)	90.3 ± 5.3	3.3
[4G]BF ₄	38.8 ± 6.9	22.9 ± 5.8	26.2 ± 5.6	25.6 ± 4.5	21.4 ± 3.6	26.9 ± 5.1 (1.3)	89.5 ± 4.5	3.3
[5H]CF ₃ SO ₃	37.4 ± 5.2	32.5 ± 4.8	30.8 ± 5.1	33.7 ± 4.2	36.2 ± 6.1	44.7 ± 6.1 (1.2)	98.3 ± 4.2	2.8
cisplatin	2.2 ± 1.4	16.5 ± 2.2	2.1 ± 0.3	12.1 ± 2.9	8.8 ± 0.2	–	18.1 ± 3.6	2.2
doxorubicin	–	–	–	–	0.2 ± 0.03	7.8 ± 2.2 (39)	–	–

cytotoxicity of tested complexes against a noncancerous cell line (HEK293) and calculated the selectivity index (SI, defined as the ratio between the IC_{50} value in noncancerous cells and the corresponding average IC_{50} value related to cancer cells; Table 5). The diiron complexes are generally less cytotoxic against HEK293 noncancerous cells, and again [2D]CF₃SO₃ exhibited the best profile (SI value of 5.6 to be compared with 2.2 for cisplatin). Overall, it appears that slight structural variations on the iminium group may have a notable impact on the activity of the cations, although not obvious: for instance, [2D]CF₃SO₃ and [2E]CF₃SO₃ differ from each other in the nature and the position of peripheral arene substituents and display almost identical $\log P_{ow}$ values, notwithstanding the former is significantly more cytotoxic and selective than the latter.

The antiproliferative activity was also investigated in a multidrug-resistant cancer cell model overexpressing P-gp (MCF-7 ADR cells). All complexes exhibited activity levels very similar on both sensitive (MCF-7) and multi-drug resistant (MCF-7ADR) cell lines; interestingly, the resistance factor (RF) values (Table 5) range from 24 to 35 times lower than that of doxorubicin, a drug belonging to the MDR spectrum, thus indicating the ability of the complexes to overcome MDR phenomena and not to act as P-gp substrates.

Cellular uptake in cancerous and noncancerous cells

In order to correlate the cytotoxic potential to the ability of the newly developed complexes to enter cells, we performed uptake experiments. To this purpose, we selected the most promising compound [2D]CF₃SO₃ ($\log P_{ow} = -0.25$) together with the less active/selective [2E]CF₃SO₃ ($\log P_{ow} = -0.27$) and [3G]CF₃SO₃ ($\log P_{ow} = +0.29$), to be assessed for their accumulation in human pancreatic PSN-1 cancer cells and in untransformed HEK293 cells. Thus, cells were treated for 24 h with equimolar concentrations (50 μ M) of the tested compounds. The cellular iron levels were quantified by means of GF-AAS analysis, and the results, expressed as μ g Fe per 10⁶ cells, are shown in Figure 4A. Complex [3G]CF₃SO₃ was ineffective in entering human cells, while both [2D]CF₃SO₃ and [2E]CF₃SO₃ were able to induce cellular iron accumulation, and no significant differences in the ability to enter cells were evidenced for the two complexes. Considering the $\log P_{ow}$ values, the obtained outcomes highlight that the hydrophilic complexes [2D]CF₃SO₃ and [2E]CF₃SO₃ are significantly more effective in entering cells compared to the more lipophilic one [3G]CF₃SO₃. In addition, both [2D]CF₃SO₃ and [2E]CF₃SO₃ led to major iron accumulation in untransformed cells with respect to pancreatic cancer cells. Intriguingly, these findings attest that their selectivity towards cancer cells with respect to untransformed ones cannot be attributable to their different ability to cross cellular plasmalemma and to enter human cells, and the reason of their preferential activity against cancer cells might be dependent on their ability to interfere with a cancer specific target.




Figure 4. Intracellular detection of iron and carbon monoxide. A) Cellular uptake in PSN-1 and HEK293 cells; cells were incubated with 50 μ M of complexes for 24 h, and the cellular iron content was detected by GFAAS analysis. B) Intracellular CO levels were determined by using a fluorescent probe (BioTracker Carbon Monoxide Probe 1 Live Cell Dye[®], Merck, Germany) after 30 min of treatment of PSN-1 or HEK293 cells with 20 μ M [2C]CF₃SO₃ and [2D]CF₃SO₃, or 20 μ M CORM-401 as positive control. ** $P < 0.01$, * $P < 0.05$.

Cytotoxic activity in 3D cell cultures

The remarkable cell-killing effect observed in 2D cultured cells prompted us to evaluate the in vitro antitumor activity of the complexes on 3D cell cultures. Differently from 2D monolayer culture, 3D spheroid cell culture systems comprise cancer cells in various cell growth stages. Consequently, the multicellular cancer spheroid model is recognized to better reflect the tumour mass in vivo regarding drug permeation, cell interactions, gene expression, hypoxia and nutrient gradients with respect to monolayer cell cultures, making 3D models more predictive than conventional 2D monolayer cultures in screening antitumor drugs.^[38] Table 6 summarizes the IC_{50} values obtained after treatment of 3D cell spheroids of human ovarian (2008) and pancreatic (PSN-1) cancer cells with the diiron complexes and cisplatin. In accordance with 2D chemosensitivity assays, compounds [2B]CF₃SO₃ and [3F]CF₃SO₃ were ineffective against cancer cells spheroids, whereas [2D]CF₃SO₃ was the

Table 6. Activity of diiron complexes in 3D cell cultures.

Compound	IC ₅₀ ± SD (μM) 2008	PSN-1
[2A]CF ₃ SO ₃	> 100	> 100
[2B]BF ₄	> 100	> 100
[2C]CF ₃ SO ₃	66.4 ± 8.6	78.2 ± 9.1
[2D]CF ₃ SO ₃	42.8 ± 4.2	53.7 ± 6.1
[2E]CF ₃ SO ₃	65.1 ± 6.8	82.3 ± 4.8
[3F]CF ₃ SO ₃	> 100	> 100
[3G]CF ₃ SO ₃	88.5 ± 3.2	> 100
[4G]BF ₄	58.9 ± 4.8	77.4 ± 8.4
[5H]CF ₃ SO ₃	73.2 ± 6.2	86.2 ± 6.4
cisplatin	57.6 ± 3.6	61.7 ± 12.1

Spheroids (2.5 × 10³ cells/well) were treated for 72 h with increasing concentrations of tested compounds. The growth-inhibitory effect was evaluated by means of the acid phosphatase (APH) test. IC₅₀ values were calculated from the dose-survival curves using a four-parameter logistic model (*p* < 0.05). SD = standard deviation.

most effective complex among the series, thus indicating its ability to better penetrate the spheroid and reach the hypoxic core. It is noteworthy that [2D]CF₃SO₃ exhibited a level of activity either comparable (PSN-1 cells) or even superior (2008 cells) to that of cisplatin.

An important aspect of the collected data is that only a limited decrease of activity is observed with the cytotoxic compounds, the IC₅₀ ratio related to 3D and 2D experiments ranging from 2 to 5 for both cell lines; in particular, this ratio is approximately 2 for the cytotoxic diiron complexes against the 2008 cell line, while the corresponding value for cisplatin is 26. Note that a substantial drop of antiproliferative activity has been often recognized for potential anticancer metal drugs in 3D cell cultures compared to the corresponding 2D ones, highlighting the need for a combination of both models for screening of compounds.^[1c]

Intracellular CO release, ROS production and inhibition of thioredoxin reductase

Additional studies were conducted in order to elucidate the mode of action underlying the cell killing effect of the newly synthesized diiron complexes in cancer cells. In particular, based on the evidence of their tendency to slowly release CO in aqueous media (see section on solubility, partition coefficient, stability in aqueous media), we evaluated the ability of the most performant complexes [2C]CF₃SO₃ and [2D]CF₃SO₃ to release carbon monoxide inside PSN-1 pancreatic cancer cells and HEK293 noncancer cells. A fluorometric test was conducted over a short time interval (30 min) by means of a CO sensing dye (Figure 4B). Interestingly, both complexes were effective in significantly release CO in PSN-1 cells whereas lower levels of CO were detected in HEK293 cells. These results attest the power of the novel diiron complexes to release CO in cellular milieu and, more importantly, could at least in part explain the tumour-selective cytotoxic effect exerted by [2C]CF₃SO₃ and [2D]CF₃SO₃. Note that the ability of a range of related diiron cyclopentadienyl complexes to release CO ligands in aqueous

environments was previously demonstrated.^[16a,39] The relatively fast release of carbon monoxide within the cell might be associated to the presence of a consistent amount and variety of biological substrates, which can quicken the formation of CO substitution diiron products. As a matter of fact, it is well documented that [2E-F]CF₃SO₃ are susceptible to replacement of one terminal CO ligand by suitable C-, P-, S- and N-donors to give adducts of general formula [Fe₂Cp₂(CO)(L)(μ-CO){μ-CNR(Me)}]^{0/+}.^[15b,16a,20] Although the nature of L in the cell context is far from being clarified, it is reasonable to speculate that CO release is readily operative via such substitution pathway. However, an acceleration of the route leading to the extensive decomposition of the diiron scaffold (elimination of three COs per complex), as observed in aqueous media, might also contribute.

Iron is a redox active metal that can generate ROS in cells via the Fenton reaction, thus inducing cellular damage and ultimately leading to cell death.^[40] Coherently, several iron complexes have been shown to exert antitumor activity through redox stress induction (see the Introduction).^[8] Based on this premises, we evaluated the effects induced by the diiron complexes on the mitochondria activity and the cellular redox environment. More precisely, we investigated the ROS production and the alteration of the mitochondrial membrane potential. Treatment of PSN-1 cells with [2C]CF₃SO₃ and [2D]CF₃SO₃ determined a substantial increase in cellular ROS production, in a time-dependent manner (Figure 5A). Remarkably, after 2 h treatment with [2D]CF₃SO₃, the hydrogen peroxide content was similar to that induced by antimycin, a classical inhibitor of the mitochondrial respiratory chain at the level of complex III. Consistently, a significant dose-dependent increase of cells with depolarized mitochondria was observed after 24 h-treatment of PSN-1 cells with [2C]CF₃SO₃ and [2D]CF₃SO₃ (Figure 5B). The time-dependent ROS basal production is probably associated to more than one phenomenon. First of all, the progressive disruption of the diiron structure leads to the extrusion of the Fe^I centres, which are expected to subsequently convert into Fe^{III} (in fact, slow precipitation of iron (III) oxides has been recognized from water solution, see above). Otherwise, based on previous voltammetric measurements on [2E-F]CF₃SO₃,^[41] oxidation of iron enclosed in the complex is out of the range of biologically relevant potentials. In the cases of [2-3]⁺, some contribution to ROS might be provided by the partial generation of the neutral products 1A-H upon CH₃⁺ elimination (see above); in principle, the absence of a net positive charge in 1A-H might favour the oxidation of these complexes or their possible derivatives in the cells.^[40]

It has recently emerged that the redox stress induced by some iron complexes might also be attributed to their ability to inhibit the selenoenzyme thioredoxin reductase (TrxR). In particular, Rigobello and co-workers reported the capacity of a ferrocenyl diphenol and of a Tamoxifen-like ferrocifen to target and hamper TrxR activity.^[42] On this basis, we thought of interest to test the ability of the most promising diiron complexes [2C]CF₃SO₃ and [2D]CF₃SO₃ to target TrxR both in cell-free experiments and in cells. The two complexes showed a similar pattern of response, being completely ineffective in




Figure 5. Effects induced by compounds [2C]CF₃SO₃ and [2D]CF₃SO₃ at the mitochondrial level. A) ROS production in PSN-1 cells. Cells were pre-incubated in phosphate-buffered saline (PBS)/10 mM glucose medium for 20 min at 37 °C in the presence of 10 mM CM-H₂DCFDA and then treated with increasing concentrations of [2C]CF₃SO₃ and [2D]CF₃SO₃ or antimycin (3 μM). The fluorescence of DCF was measured at λ_{ex} = 485 nm and λ_{em} = 527 nm. B) Effects of [2C]CF₃SO₃ and [2D]CF₃SO₃ on mitochondrial membrane potential. PSN-1 cells were treated for 24 h with increasing concentrations of [2C]CF₃SO₃ and [2D]CF₃SO₃ or antimycin (3 μM) and stained with TMRM (10 nM). Fluorescence was estimated at λ_{ex} = 490 nm and λ_{em} = 590 nm. Data are the means of five independent experiments. Error bars indicate S.D. *P < 0.05.

hampering TrxR in cell-free experiment (data not shown) but elicited a substantial inhibition of the selenoenzyme in human pancreatic PSN-1 cancer cells (Figure 6). In particular, PSN-1 cells treated with 25 μM of [2C]CF₃SO₃ and [2D]CF₃SO₃ for 24 h showed a residual TrxR cellular activity of 57 and 39%, respectively. These data well correlate with the observed formation of carbon monoxide in cells, and suggest that the inhibition of TrxR is ascribable to the interaction with diiron complexes and organic fragments generated from [2–5]⁺ by dissociation of CO ligand(s). On the other hand, TrxR inhibition might also be consistent with the capacity of the complexes to




Figure 6. Effects of compounds [2C]CF₃SO₃, [2D]CF₃SO₃ and Auranofin as positive control on TrxR in human pancreatic cells. PSN-1 cells were incubated for 24 h with the IC₅₀ of tested compounds. Afterwards, cells were washed twice with PBS and lysed. TrxR activity was tested by measuring the NADPH-dependent reduction of DTNB. *P < 0.05.

methylate specific substrates, as we have assessed for lysozyme. Actually, it was previously described that several alkylating agents are able to selectively modify the redox active Cys or Sec of TrxR, thus causing irreversible inhibition.^[43]

Conclusions

We have described a synthetic strategy to obtain a family of diiron carbonyl complexes containing a bridging aminocarbonyne/iminium hybrid ligand from the readily available [Fe₂Cp₂(CO)₄]. They have ideal properties for a potential anticancer drug, such as the presence of a nontoxic metal element, appreciable water solubility and amphiphilicity, and stability in aqueous media.^[44] Moreover, the synthesis works up to multigram scales and features a considerable structural variability. In general, the complexes showed moderate cytotoxic activity against human cancer cells and the ability to overcome resistance. Compound [2D]CF₃SO₃, with a 4-methoxy phenyl substituent on the bridging hydrocarbyl ligand, was revealed to be the most promising and exhibited a noteworthy selectivity toward cancer cell lines compared to noncancerous cells. According to cellular-uptake experiments, such selectivity is not correlated to a different ability to enter cancerous or noncancerous cells. Remarkably, the cytotoxicity profile of the complexes does not substantially decrease in 3D cell cultures, in contrast to what has often been observed in the literature upon comparison of 2D/3D studies on various transition metal compounds. Interestingly, the activity exhibited by [2D]CF₃SO₃ in the ovarian cancer cell 3D model was even superior to that of cisplatin. Experiments on selected complexes outlined their power to behave as carbon monoxide-releasing molecules

(CORMs) inside cells, to unbalance cellular redox homeostasis and to alkylate biological targets. The preferential CO release in cancer cells with respect to untransformed cells could, at least in part, be consistent with the ability to target TrxR. Actually, it is well known that the Trx system is overexpressed in cancer cells, and has been recognized as a tumour-specific target for the development of selective anticancer agents. In summary, we suggest that a simple diiron platform might offer an arsenal of tools not available for widely investigated ferrocenes, paving the way for the development of iron-based drugs with optimized features. Further biochemical and biophysical studies will be performed to clarify in more detail the mechanism of action of this new class of organometallic anticancer candidates.

Experimental Section


General experimental details: $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ (99%) was purchased from Strem Chemicals, other reactants and solvents were obtained from Alfa Aesar, Merck, Apollo Scientific or TCI Chemicals and were of the highest purity available. Isocyanides were stored at 4 °C or –20 °C and used as received; contaminated labware was treated with bleach. Methyl triflate was stored under N_2 at 4 °C; allyl iodide and triethyloxonium tetrafluoroborate (1 M solution in CH_2Cl_2) were stored under N_2 at –20 °C. Compounds **[1A–H]**^[19] and **[2D–F]** CF_3SO_3 ^[20,21] were prepared according to published procedures. Alkylation reactions were carried out under dry N_2 using standard Schlenk techniques and solvents distilled over appropriate drying agents (MeCN from CaH_2 , CH_2Cl_2 from P_2O_5). The synthesis and chromatographic purification of **6** was carried out under N_2 using deaerated solvents. Anion-exchange reactions and all other operations were conducted under air with common laboratory glassware. Chromatography separations were carried out on alumina columns (Merck; neutral, 4% w/w water content except where otherwise noted). Ion-exchange chromatography was performed with an Amberlyst® 15 hydrogen form resin (Superlco/Merck), pre-activated with a methanolic solution of NaOH. Once isolated, compounds **[2B]X** ($\text{X} = \text{CF}_3\text{SO}_3, \text{BF}_4$), **[2C]Cl**, **[5H]** CF_3SO_3 (hygroscopic) and **6** were stored under N_2 ; all other Fe compounds being air- and moisture-stable in the solid state. NMR spectra were recorded at 25 °C on a Bruker Avance II DRX400 instrument equipped with a BBFO broadband probe. Chemical shifts (expressed in parts per million) are referenced to the residual solvent peaks^[45] (^1H , ^{13}C) or to external standards^[46] (^{14}N to CH_3NO_2 ; ^{19}F to CFCl_3 , ^{35}Cl to 1 M NaCl in D_2O , ^{31}P to 85% H_3PO_4). In $[\text{D}_6]\text{DMSO}/\text{D}_2\text{O}$ mixtures, ^1H chemical shifts are referenced to the $[\text{D}_5]\text{DMSO}$ signal as in pure $[\text{D}_6]\text{DMSO}$ ($\delta/\text{ppm} = 2.50$); in $\text{D}_2\text{O}/\text{CD}_3\text{OD}$ mixtures, ^1H chemical shifts are referenced to the CD_3OD residual peak as CH_3OH in pure D_2O ($\delta/\text{ppm} = 3.34$). ^1H and ^{13}C spectra were assigned with the assistance of $^1\text{H}\{^{31}\text{P}\}$, ^{13}C DEPT 135, $^1\text{H}, ^1\text{H}$ COSY, $^1\text{H}-^{13}\text{C}$ *gs*-HSQC and $^1\text{H}-^{13}\text{C}$ *gs*-HMBC experiments.^[47] CDCl_3 stored in the dark over Na_2CO_3 was used for NMR analysis. IR spectra of solid samples ($650\text{--}4000\text{ cm}^{-1}$) were recorded on a Perkin Elmer Spectrum One FTIR spectrometer, equipped with a UATR sampling accessory; IR spectra of solutions were recorded using a CaF_2 liquid transmission cell ($2300\text{--}1500\text{ cm}^{-1}$) on a Perkin Elmer Spectrum 100 FTIR spectrometer. UV/Vis spectra ($250\text{--}800\text{ nm}$) were recorded on a Ultraspec 2100 Pro spectrophotometer using PMMA cuvettes (1 cm path length). IR and UV/Vis spectra were processed with Spectragryph software.^[48] Carbon, hydrogen and nitrogen analyses were performed on a Vario MICRO cube instrument (Elementar). GC analysis was performed on a Clarus 500 instrument (PerkinElmer) equipped with a 5 Å MS packed column (Supelco) and a TCD detector. Samples

were analysed by isothermal runs (110 °C, 4 min) using He as carrier gas. Raman analysis was conducted with a Renishaw Invia micro-Raman instrument equipped with a Nd:YAG laser working at 532 nm and 0.1 mW, integration time 10 s. HPLC-MS analyses were performed with a API3000 instrument (SCIEX) equipped with ESI(+) source and a quadrupole detector. HPLC separation was performed using an Agilent 1110 series instrument (Agilent Technologies Deutschland GmbH, Germany) equipped with a G1312A binary pump, a G1329A autosampler, a peltier column oven Series 200 (PerkinElmer) and a BioZen C4 intact column (3.6 μm , $150 \times 2.1\text{ mm}$, pore size 200 Å; Phenomenex, USA).

Synthesis and characterization of compounds

$[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNR})]$, **[1A–H].^[19] *General procedure.* In a 250 mL round-bottom flask equipped with a reflux condenser under N_2 , the selected isocyanide, or its solution in MeCN (10 mL, for solid compounds), was added dropwise to a suspension of $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ (1.6 equiv) in anhydrous MeCN (80–100 mL). Alkyl isocyanides: the mixture was heated at reflux ($T \geq 100\text{ °C}$) for 8 h, then stirred at room temperature for additional 14 h. Aryl isocyanides: the mixture was stirred at room temperature for 14 h then heated at reflux ($T \geq 100\text{ °C}$) for 1–3 h. Next, conversion was checked by IR and the dark red-brown suspension was dried under vacuum (40 °C). The resulting solid, consisting of a mixture of $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ and $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNR})]$, was directly used in the following alkylation procedure without any purification.**


$[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})\{\mu\text{-CNMe(1H-indol-6-yl)}\}]\text{CF}_3\text{SO}_3$, **[2A] CF_3SO_3**



In a 150 mL Schlenk tube under N_2 , $\text{CF}_3\text{SO}_3\text{Me}$ (0.11 mL, 1.0 mmol) was added dropwise to a dark red suspension of **1A** (0.975 mmol) in anhydrous CH_2Cl_2 (50 mL) under stirring. Therefore, the mixture was stirred at room temperature for 6 h and conversion was checked by IR (CH_2Cl_2). Next the suspension (red solution + solid) was moved on top of an alumina column (*h* 7, *d* 4.3 cm). Impurities were eluted with neat CH_2Cl_2 and THF, then a raspberry red band containing the title product was eluted with neat MeCN. Volatiles were removed under vacuum and residue was triturated in Et_2O . The suspension was stirred at room temperature for a few hours and then filtered. The resulting red solid was washed with toluene, Et_2O and dried under vacuum (40 °C). Yield: 358 mg, 71%. Compound **[2A]** CF_3SO_3 is soluble in MeCN, THF, MeOH, CH_2Cl_2 , less soluble in CH_2Cl_2 , CHCl_3 , insoluble in Et_2O , toluene and water. X-ray quality crystals of **[2A]** CF_3SO_3 were obtained from an acetone solution layered with Et_2O and settled aside at –20 °C. Anal. calcd. for $\text{C}_{25}\text{H}_{21}\text{F}_3\text{Fe}_2\text{N}_2\text{O}_6\text{S}$: C 46.47, H 3.28, N 4.34; found: C 46.09, H 3.28, N 4.34. IR (solid state): $\nu/\text{cm}^{-1} = 3330\text{w-br}$ (ν_{NH}), 3114w, 2004 s (ν_{CO}), 1985 s (ν_{CO}), 1833 s ($\nu_{\mu\text{-CO}}$), 1583w-sh, 1555 m, 1540 m (ν_{CN}), 1475w, 1458w, 1433w, 1420w, 1397 m, 1361w, 1345w, 1323w, 1290–1276 m, 1244 s (ν_{SO_3}), 1223 s (ν_{SO_3}), 1154 s (ν_{SO_3}), 1107 m-sh, 1067w, 1028 s, 1016 s-sh, 1002 m-sh, 942w, 931w, 893w, 875w, 860 m, 845 m, 817w, 797 m, 772 s, 756w-sh, 743 m-sh, 728 m. IR (CH_2Cl_2): $\nu/\text{cm}^{-1} = 2022\text{ s}$ (ν_{CO}), 1992 m-sh (ν_{CO}), 1836 s ($\nu_{\mu\text{-CO}}$), 1554 m, 1542 m (ν_{CN}). IR (MeCN): $\nu/\text{cm}^{-1} = 2023\text{ s}$ (ν_{CO}), 1991 m-sh (ν_{CO}), 1836 s ($\nu_{\mu\text{-CO}}$), 1554 m, 1542 m-sh (ν_{CN}). ^1H NMR (CD_3CN): $\delta/$

ppm = 9.78 (s-br, 1H, NH), 7.85 (s-br, 1H, C9-H), 7.70 (d, $^3J_{\text{HH}} = 8.6$ Hz, 1H, C4-H), 7.48 (t, $^3J_{\text{HH}} = 2.7$ Hz, 1H, C6-H), 7.37 (d-br, $^3J_{\text{HH}} = 7.2$ Hz, 1H, C3-H), 6.67–6.62 (m, 1H, C7); 5.39, 4.65 (s, 10H, Cp), 4.53 (s, 3H, C1). $^{13}\text{C}\{^1\text{H}\}$ NMR (CD_3CN): $\delta/\text{ppm} = 324.9$ (CN), 255.9 ($\mu\text{-CO}$); 209.8, 209.2 (CO); 144.6 (C2), 136.3 (C5), 129.1 (C8), 128.8 (C6), 118.8 (C3), 117.3 (C9), 113.8 (C4), 103.5 (C7); 91.2, 91.0 (Cp); 58.5 (C1). $^{19}\text{F}\{^1\text{H}\}$ NMR (CD_3CN): $\delta/\text{ppm} = -79.3$. ^1H NMR (CDCl_3): $\delta/\text{ppm} = 9.57$ (s-br, 1H, NH), 8.0–7.0 (br, C3-H + C9-H), (7.65 (d, $^3J_{\text{HH}} = 8.4$ Hz, 1H, C4-H), 7.42–7.39 (m, 1H, C6-H), 6.60 (s-br, 1H, C7-H); 5.41, 4.63 (s, 10H, Cp); 4.56 (s, 3H, C1-H).

[Fe₂Cp₂(CO)₂($\mu\text{-CO}$){ $\mu\text{-CNMe}(\text{CH}_2\text{PO}_3\text{Et}_2)$ }]X, **[2B]X** (X = BF₄, CF₃SO₃)




[2B]CF₃SO₃. In a 150 mL Schlenk tube under N₂, CF₃SO₃Me (0.20 mL, 1.8 mmol) was added dropwise to a dark red solution of **1B** (1.38 mmol) in anhydrous CH₂Cl₂ (40 mL) under stirring. Therefore, the mixture was stirred at room temperature for 7 h and conversion was checked by IR (CH₂Cl₂). Next, the solution was moved on top of an alumina column (*h* 8, *d* 5.5 cm). Impurities were eluted with neat CH₂Cl₂, THF and MeCN, then a red band containing the title product was eluted with MeCN/MeOH (10:1, *v/v*). Volatiles were removed under vacuum (40 °C), affording a red, highly hygroscopic solid. Yield: quantitative. IR (CH₂Cl₂): $\nu/\text{cm}^{-1} = 2028$ s (ν_{CO}), 1997w-sh (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$). ^1H NMR (CDCl_3): $\delta/\text{ppm} = 5.32$ (s, 10H, Cp), 5.23 (dd, $^2J_{\text{HH}} = 14.9$ Hz, $^2J_{\text{HP}} = 5.3$ Hz, 1H, C2-H), 4.93 (t, $^2J_{\text{HH}} = ^2J_{\text{HP}} = 15.5$ Hz, 1H, C2-H'), 4.38 (s, 3H, C1-H), 4.23–4.10 (m, 4H, C3-H), 1.30 (q, $^4J_{\text{HP}} = ^3J_{\text{HH}} = 7.1$ Hz, 6H, C4-H). $^{19}\text{F}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = -78.2$. $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = 17.3$.

[2B]BF₄. In a 500 mL round bottom flask, **[2B]CF₃SO₃** was suspended in water (100 mL) with vigorous stirring until completely dissolved then treated with NaBF₄ (500 mg). The red solution was extracted with CH₂Cl₂ (3 × 20 mL) and the combined organic fractions were dried under vacuum. The residue was suspended in water and the ion exchange procedure with NaBF₄ was repeated (×3); $^{19}\text{F}\{^1\text{H}\}$ NMR analysis of the final CH₂Cl₂ solution indicated the complete removal of CF₃SO₃[−] anions. Therefore, volatiles were removed under vacuum; the residue was dissolved in CH₂Cl₂ and filtered over celite. A red foamy hygroscopic solid, obtained upon volatiles removal without heating, was dried under vacuum and stored under N₂. Yield: 751 mg, 90% (with respect to **1B**). Compound **[2B]BF₄** is soluble in MeOH, MeCN, CH₂Cl₂, CHCl₃, water, insoluble in Et₂O and hexane. Anal. calcd. for C₂₀H₂₅BF₄Fe₂NO₆P: C 39.71, H 4.17, N 2.31; found: C 39.20, H 4.25, N 2.26. IR (solid state): $\nu/\text{cm}^{-1} = 3117\text{w}$, 2987w, 2938w, 2913w, 2875w, 2012 s (ν_{CO}), 1986 s-sh (ν_{CO}), 1823 s ($\nu_{\mu\text{-CO}}$), 1568 m (ν_{CN}), 1479w, 1446w, 1435w, 1421w, 1399 m, 1370w-sh, 1297–1286w, 1254 m, 1225 m-sh, 1180w, 1163w, 1075 m-sh, 1033 s-sh (ν_{BF_4}), 1008 s, 973 s, 951 s-sh, 904 m, 864 m-sh, 851 m, 837 m-sh, 780s, 745 s, 710 m-sh. IR (CH₂Cl₂): $\nu/\text{cm}^{-1} = 2028$ s (ν_{CO}), 1996w (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$), 1574w (ν_{CN}). IR (MeCN): $\nu/\text{cm}^{-1} = 2026$ s (ν_{CO}), 1994w (ν_{CO}), 1838 m ($\nu_{\mu\text{-CO}}$), 1569w (ν_{CN}). ^1H NMR (CDCl_3): $\delta/\text{ppm} = 5.29$ (s, 10H, Cp), 5.15 (dd, $^2J_{\text{HH}} = 16.4$ Hz, $^2J_{\text{HP}} = 4.0$ Hz, 1H, C2-H), 4.93 (t, $^2J_{\text{HH}} = ^2J_{\text{HP}} = 15.6$ Hz, 1H, C2-H'), 4.35 (s, 3H, C1-H), 4.24–4.10 (m, 4H, C3-H), 1.30 (dt, $^4J_{\text{HP}} = 9.8$ Hz, $^3J_{\text{HH}} = 7.1$ Hz, 6H, C4-H). No changes were observed in the ^1H spectrum after 14 h at

room temperature. $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = 323.7$ (d, $^3J_{\text{CP}} = 6.4$ Hz, CN), 254.7 ($\mu\text{-CO}$); 207.4, 207.1 (CO); 90.3, 90.1 (Cp); 63.3 (C3), 62.5 (d, $^1J_{\text{CP}} = 146$ Hz, C2), 53.2 (C1), 16.4 (t, $^3J_{\text{CP}} = 5.6$ Hz, C4). $^{19}\text{F}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = -151.9$ ($^{19}\text{BF}_4$), -152.0 ($^{11}\text{BF}_4$). $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = 17.3$.

[Fe₂Cp₂(CO)₂($\mu\text{-CO}$){ $\mu\text{-CNMe}(\text{C}_6\text{H}_{11})$ }]X, **[2C]X** (X = CF₃SO₃, Cl)




[2C]CF₃SO₃. In a 500 mL round bottom Schlenk flask under N₂, CF₃SO₃Me (2.8 mL, 26 mmol) was added dropwise to a dark red suspension of **1C** (22.5 mmol) in anhydrous CH₂Cl₂ (100 mL) under stirring. Therefore, the mixture was stirred at room temperature for 4 h and the conversion was checked by IR (CH₂Cl₂). Next, the dark red solution was moved on top of an alumina column (*h* 13, *d* 6 cm). Impurities were eluted with neat CH₂Cl₂ and THF, then a red band containing **[2C]CF₃SO₃** was eluted with MeCN/MeOH (20:1, *v/v*). A red band, containing a minor fraction of **[2C]Cl**, was collected using MeOH as eluent. Volatiles were removed under vacuum from the MeCN/MeOH solution and residue was triturated in Et₂O. The suspension was stirred at room temperature for a few h then filtered. The resulting red solid was washed with toluene, Et₂O and dried under vacuum (40 °C). Yield: 11.44 g, 85%. Compound **[2C]CF₃SO₃** is soluble in MeCN, MeOH, CH₂Cl₂, CHCl₃, less soluble in water, poorly soluble in toluene, insoluble in Et₂O, hexane. X-ray-quality crystals of **[2C]CF₃SO₃** were obtained from a CH₂Cl₂ solution layered with heptane and settled aside at −20 °C. Anal. calcd. for C₂₂H₂₄F₃Fe₂NO₆S: C 44.10, H 4.04, N, 2.34; found: C 44.47, H 4.04, N, 2.34. IR (solid state): $\nu/\text{cm}^{-1} = 3102\text{w}$, 2937w, 2862w, 2185w, 2146w, 2006 s (ν_{CO}), 1982 s-sh (ν_{CO}), 1822 s ($\nu_{\mu\text{-CO}}$), 1565 m (ν_{CN}), 1544 m-sh, 1452w, 1435w, 1421w, 1402w, 1366w, 1352w, 1321w, 1272 s-sh, 1257 s (ν_{SO_3}), 1223 s-sh (ν_{SO_3}), 1150s (ν_{SO_3}), 1056 m, 1029 s, 990 m, 864 m, 854 m, 796 s, 746 s. IR (CH₂Cl₂): $\nu/\text{cm}^{-1} = 2020\text{s}$ (ν_{CO}), 1988w-sh (ν_{CO}), 1835 m ($\nu_{\mu\text{-CO}}$), 1567w (ν_{CN}). IR (MeCN): $\nu/\text{cm}^{-1} = 2021$ s (ν_{CO}), 1988w-sh (ν_{CO}), 1835 m ($\nu_{\mu\text{-CO}}$), 1568w (ν_{CN}). ^1H NMR (CDCl_3): $\delta/\text{ppm} = 5.36$, 5.27 (s, 10H, Cp); 4.68 (t, $^3J_{\text{HH}} = 11.7$ Hz, 1H, C2-H), 4.06 (s, 3H, C1-H), 2.81 (d, $J = 11.8$ Hz, 1H, C4-H), 2.15 (d, $J = 14.6$ Hz, 1H, C6-H), 2.03–1.94 (m, 2H, C3-H + C4-H'), 1.86–1.72 (m, 3H, C7-H + C5-H), 1.53–1.35 (m, 3H, C3-H' + C6-H'), 1.34–1.20 (m, 1H, C7-H'). No changes were observed in the ^1H spectrum after 14 h at room temperature. $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = 316.4$ (CN), 255.3 ($\mu\text{-CO}$); 208.5, 207.6 (CO); 90.3, 90.1 (Cp); 79.8 (C2), 46.8 (C1), 31.2 (C5), 30.7 (C4), 26.1 (C3), 26.0 (C6), 25.1 (C7). $^{19}\text{F}\{^1\text{H}\}$ NMR (CDCl_3): $\delta/\text{ppm} = -78.2$. ^1H NMR (CD_3OD): $\delta/\text{ppm} = 5.40$, 5.36 (s, 10H, Cp), 4.07 (s, 3H, C1-H), 2.41 (d, $J = 11.1$ Hz, 1H, C4-H), 2.17–2.07, 2.03–1.91, 1.85–1.50, 1.42–1.32 (m, C₆H₁₁).

[2C]Cl. Compound **[2C]CF₃SO₃** (110 mg, 0.184 mmol) was dissolved in MeOH (2 mL) then moved on top of an Amberlyst 15 column (Na⁺ form; *h* 7 cm, *d* 2.3 cm). NaCF₃SO₃ was eluted with neat MeOH then a red band containing **[2C]⁺** was eluted with NaCl-saturated MeOH. Volatiles were removed under vacuum and the residue was suspended in MeCN. The suspension was filtered over celite; the filtrate was checked for absence of CF₃SO₃[−] by ^{19}F NMR then dried under vacuum (40 °C). The resulting red, hygroscopic solid was


stored under N₂. Yield: 83 mg, 93%. Compound [2C]Cl shows the same solubility pattern as the triflate salt. X-ray quality crystals of [2C]Cl·2.34H₂O were obtained from a CH₂Cl₂ solution layered with hexane and settled aside at -20 °C. Anal. calcd. for C₂₁H₂₄ClFe₂NO₃: C 51.94, H 4.98, N 2.88; found: C 51.99, H 5.02, N 2.83. IR (solid state): ν/cm^{-1} = 3376 m-br* (ν_{OH}), 3098–3059w, 2933 m, 2858w, 2180–2160w, 1997 s (ν_{CO}), 1969 s-sh (ν_{CO}), 1811 s ($\nu_{\mu\text{-CO}}$), 1662w, 1631w, 1565 s (ν_{CN}), 1543 m, 1450 m, 1434w, 1419 m, 1400 m, 1350w, 1319w, 1263w-sh, 1249w, 1173w, 1154w, 1054 m, 1026w, 1015w, 990 m, 924w-sh, 893w-sh, 852 m, 795 s, 746 s, 729 s-sh. *Due to moisture. IR (CH₂Cl₂): ν/cm^{-1} = 2018 s (ν_{CO}), 1985w-sh (ν_{CO}), 1833 m ($\nu_{\mu\text{-CO}}$), 1569w (ν_{CN}). IR (MeCN): ν/cm^{-1} = 2020s (ν_{CO}), 1987w-sh (ν_{CO}), 1834 m ($\nu_{\mu\text{-CO}}$), 1568w (ν_{CN}). ¹H NMR (CDCl₃): δ/ppm = 5.51, 5.39 (s, 10H, Cp); 4.75–4.66 (m, 1H, C2-H), 4.14 (s, 3H, C1-H), 3.16 (d, ²J_{HH} = 13.4 Hz, 1H, C4-H), 2.15 (d, ²J_{HH} = 14.2 Hz, 1H, C6-H), 2.03–1.93 (m, 2H, C3-H + C4-H'), 1.84–1.72 (m, 3H, C7-H + C5-H), 1.51–1.35 (m, 2H, C3-H' + C6-H'), 1.33–1.23 (m, 1H, C7-H'). No changes were observed in the ¹H spectrum after 24 h at room temperature. ¹³C {¹H} NMR (CDCl₃): δ/ppm = 316.2 (CN), 255.8 ($\mu\text{-CO}$); 208.7, 207.8 (CO); 90.7, 90.3 (Cp); 79.7 (C2), 47.1 (C1), 31.3 (C5), 31.0 (C4), 26.1 (C3), 26.0 (C6), 25.2 (C7). ³⁵Cl NMR (CDCl₃): δ/ppm = 7.61 ($\Delta\nu_{1/2}$ = 266 Hz).

[Fe₂Cp₂(CO)₂($\mu\text{-CO}$){ $\mu\text{-CNMe(4-C}_6\text{H}_4\text{OMe)}$ }]CF₃SO₃, [2D]CF₃SO₃




The title compound was prepared with minor modifications of the literature procedure.^[21] In a 250 mL Schlenk tube under N₂, CF₃SO₃Me (1.0 mL, 5.5 mmol) was added dropwise to a dark red solution of **1B** (4.63 mmol) in anhydrous CH₂Cl₂ (40 mL) under stirring. The mixture was stirred at room temperature for 5.5 h then moved on top of an alumina column (Brockmann activity I; *h* 6.0, *d* 4.3 cm). Impurities were eluted with CH₂Cl₂ and CH₂Cl₂/THF (1 : 1, *v/v*), then a red band containing [2D]CF₃SO₃ was eluted with neat MeCN. Volatiles were removed under vacuum (40 °C) to afford a red foamy solid. Yield: 2.446 g, 85%. Compound [2D]CF₃SO₃ is soluble in MeCN, MeOH, CH₂Cl₂, CHCl₃, water, insoluble in Et₂O and hexane. X-ray quality crystals of [2D]CF₃SO₃ were obtained from a CHCl₃ solution layered with hexane and settled aside at -20 °C. Anal. calcd. for C₂₃H₂₀F₃Fe₂NO₇S: C 44.33, H 3.24, N 2.25; found: C 43.92, H 3.31, N 2.17. IR (solid state): ν/cm^{-1} = 3113w, 3091w, 2946w, 2849w, 2011 s (ν_{CO}), 1978 s (ν_{CO}), 1821 s ($\nu_{\mu\text{-CO}}$), 1608w, 1563 m, 1539 m (ν_{CN}), 1506 s, 1468w, 1449w, 1433w, 1420w, 1395 m, 1304w-sh, 1278 s, 1251 s (ν_{SO_3}), 1224 s-sh (ν_{SO_3}), 1176 m-sh, 1146 s (ν_{SO_3}), 1117 m-sh, 1108 m, 1067w, 1028 s, 890w, 855 s, 825w-sh, 773 s, 756 m-sh, 736w, 702 s. IR (CH₂Cl₂): ν/cm^{-1} = 2021 s (ν_{CO}), 1989w (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$), 1607w, 1562w, 1540w (ν_{CN}), 1507 m. IR (MeCN): ν/cm^{-1} = 2024 s (ν_{CO}), 1991w (ν_{CO}), 1837 m ($\nu_{\mu\text{-CO}}$), 1610w, 1563w, 1539w (ν_{CN}), 1508w. ¹H NMR (CDCl₃): δ/ppm = 8.3–7.6 (br, 2H, C3-H), 7.10 (d, ³J_{HH} = 7.4 Hz, 2H, C4-H); 5.43, 4.78 (s, 10H, Cp); 4.54 (s, 3H, C1-H), 3.90 (s, 3H, C6-H). ¹⁹F {¹H} NMR (CDCl₃): δ/ppm = -78.1.

[Fe₂Cp₂(CO)₂($\mu\text{-CO}$){ $\mu\text{-CNMe(CH}_2\text{CHCH}_2\text{)}}\text{]}X$, [3F]X (X = I, CF₃SO₃)




[3F]I. The preparation of the title compound was optimized with respect to the literature (69% yield with 10–30 equiv. of allyl iodide).^[22] In a 150 mL Schlenk tube under N₂, allyl iodide (0.39 mL, 4.3 mmol) was added dropwise to a dark red solution of **1F** (1.54 mmol) in anhydrous MeCN (30 mL) under vigorous stirring. The mixture was stirred for 4.5 h under protection from the light and conversion was checked by IR (MeCN). Next, the dark red solution was moved on top of an alumina column (Brockmann activity I; *h* 6.5, *d* 4.3 cm). Impurities were eluted with neat Et₂O, THF and MeCN, then a red band containing the title product was eluted with MeCN/MeOH (10 : 1, *v/v*). Volatiles were removed under vacuum (40 °C) and the residue was triturated in Et₂O. The suspension was stirred at room temperature then filtered. The resulting red solid was washed with Et₂O and dried under vacuum (40 °C). Yield: 646 mg, 78%. Compound [3F]I is soluble in MeOH, CH₂Cl₂, CHCl₃, poorly soluble in water, insoluble in Et₂O, hexane. IR (CH₂Cl₂): ν/cm^{-1} = 2021 s (ν_{CO}), 1989w (ν_{CO}), 1835 m ($\nu_{\mu\text{-CO}}$), 1585w (ν_{CN}). ¹H NMR (CDCl₃): δ/ppm = 6.09–5.97 (m, 1H, CH=C, C3-H), 5.53–5.46 (m, 3H, C2-H + C4-H); 5.45, 5.53 (s, 10H, Cp); 5.17–5.11 (m, 1H, C2-H'), 4.25 (s, 3H, C1-H).

[3F]CF₃SO₃. In a 50 mL round bottom flask, a solution of Ag(CF₃SO₃) (468 mg, 1.79 mmol) in MeCN (5 mL) was added to a dark red suspension of [3F]I (950 mg, 1.78 mmol) in MeCN (6 mL) at 0 °C. The mixture stirred at 0 °C for 2.5 h while maintaining the system under protection from the light. The resulting suspension (dark red solution + yellow AgI precipitate) was filtered over celite. Volatiles were removed under vacuum from the filtrate solution and the residue was triturated in a Et₂O/toluene mixture. The suspension was stirred at room temperature for a few h, then filtered. The resulting red solid was washed with toluene, Et₂O and dried under vacuum (40 °C). Yield: 928 mg, 94%. Compound [3F]CF₃SO₃ is soluble in MeCN, acetone, MeOH, water, less soluble in CH₂Cl₂ > CHCl₃, poorly soluble in toluene, insoluble in Et₂O. Anal. calcd. for C₁₉H₁₈F₃Fe₂NO₆S: C 40.96, H 3.26, N 2.51; found: C 41.20, H 3.20, N 2.72. IR (solid state): ν/cm^{-1} = 3106w, 2213w, 2178w, 2012 s (ν_{CO}), 1988 s (ν_{CO}), 1813 s ($\nu_{\mu\text{-CO}}$), 1644w, 1581 m (ν_{CN}), 1435w, 1416w, 1395w, 1261 s (ν_{SO_3}), 1243 s-sh, 1222 m-sh (ν_{SO_3}), 1169 s (ν_{SO_3}), 1050 m, 1028 s, 989w-sh, 931 m, 888 m, 854 m, 758 s, 666 m. IR (CH₂Cl₂): ν/cm^{-1} = 2022 s (ν_{CO}), 1990w (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$), 1584 m (ν_{CN}). IR (MeCN): ν/cm^{-1} = 2023 s (ν_{CO}), 1990w (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$), 1582 m (ν_{CN}). ¹H NMR (CDCl₃): δ/ppm = 5.98 (dddd, ³J_{HH} = 17.4, 10.0, 7.5, 5.0 Hz, 1H, C3-H), 5.50–5.45 (m, 2H, C4-H + C4-H'); 5.34, 5.32 (s, 10H, Cp); 5.30–5.23 (m, 1H, C2-H), 5.15–5.08 (m, 1H, C2-H'), 4.17 (s, 3H, C1-H). No changes were observed in the ¹H spectrum after 14 h at room temperature. ¹³C {¹H} NMR (CDCl₃): δ/ppm = 318.1 (CN), 255.3 ($\mu\text{-CO}$); 208.1, 207.8 (CO), 130.2 (C3), 122.2 (C4), 121.0 (¹J_{CF} = 319 Hz, CF₃); 90.20, 90.16 (Cp); 70.6 (C2), 51.3 (C1). ¹⁹F {¹H} NMR (CDCl₃): δ/ppm = -78.2. ¹H NMR ([D₆]acetone): δ/ppm = 6.33–6.19 (m, 1H, C3-H), 5.62 (d, ³J_{HH} = 17.2 Hz, 1H, C4-H); 5.58, 5.54 (s, 10H, Cp); 5.41–5.16 (m, 3H, C2-H + C2-H' + C4-H'), 4.28 (s, 3H, C1-H).


[Fe₂Cp₂(CO)₂(μ-CO){μ-CNMe(2-naphthyl)}]I, [3G]I


In a 25 mL Schlenk tube under N₂, methyl iodide (110 mL, 1.8 mmol) was added to a dark red solution of **1G** (0.48 mmol) in anhydrous MeCN (8 mL). The mixture was stirred for 2.5 h and conversion was checked by IR (MeCN). Next, the dark red solution was moved on top of an alumina column (*h* 10, *d* 2 cm). Impurities were eluted with neat CH₂Cl₂ and THF, then a red band containing the title product was eluted with THF/MeOH (4:1, *v/v*). Next, volatiles were removed under vacuum and the residue was dissolved in CH₂Cl₂. The suspension was filtered over celite and the filtrate was taken to dryness under vacuum (40 °C), affording a dark red solid. Yield: 208 mg, 69%. A considerable decrease in yield and purity was observed for reactions carried out in refluxing CHCl₃ or in MeCN at lower temperatures. Anal. calcd. for C₂₅H₂₀Fe₂INO₃: C 48.35, H 3.25, N 2.56; found: C 48.20, H 3.15, N 2.49. Compound **[3G]I** is soluble in MeOH, CH₂Cl₂, CHCl₃, sparingly soluble in water, insoluble in hexane. IR (CH₂Cl₂): $\tilde{\nu}/\text{cm}^{-1}$ = 2021 s (ν_{CO}), 1989 m-sh (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$), 1538w (ν_{CN}). ¹H NMR (CDCl₃): δ/ppm = 8.10 (d + m, 2H), 7.98–7.95 (m, 1H), 7.94–7.77 (m, 1H), 7.66–7.52 (m, 2H), 7.55–7.47 (m, 1H) (C₁₀H₇); 5.62, 4.82 (s, 10H, Cp); 4.75 (s, 3H, NCMe).

[Fe₂Cp₂(CO)₂(μ-CO){μ-CNEt(2-naphthyl)}]BF₄, [4G]BF₄


In a 150 mL Schlenk tube under N₂, [Et₃O]BF₄ (1 M solution in CH₂Cl₂; 0.71 mL, 0.71 mmol) was added dropwise to a dark red solution of **1G** (0.724 mmol) in anhydrous MeCN (30 mL) at 0 °C under vigorous stirring. Therefore, the mixture was stirred for 3 h, while allowing to reach room temperature. Next, conversion was checked by IR (MeCN) then volatiles were removed under vacuum. The residue was dissolved in a small volume of THF then moved on top of an alumina column (*h* 6.5, *d* 4.3 cm). Impurities were eluted with neat Et₂O and THF, then a red band containing the title product was eluted with MeCN/MeOH (10:1, *v/v*). Volatiles were removed under vacuum (40 °C) and the residue was triturated in Et₂O. The suspension was stirred at room temperature for a few h then filtered. The resulting dark red solid was washed with Et₂O and dried under vacuum (40 °C). Yield: 284 mg, 66%. A considerable decrease in yield and purity was observed for reactions carried out in CH₂Cl₂ or in MeCN at room temperature. Compound **[4G]BF₄** is soluble in MeOH, MeCN, CH₂Cl₂, CHCl₃, poorly soluble in Et₂O, insoluble in water. Anal. calcd. for C₂₆H₂₂BF₄Fe₂NO₃: C 52.49, H 3.72, N 2.35; found: C 52.11, H 3.67, N 2.30. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3116w, 3060w, 2979w, 2937w, 2160w-br, 2007 s (ν_{CO}), 1937 s-sh

(ν_{CO}), 1836 s ($\nu_{\mu\text{-CO}}$), 1596w, 1532 s (ν_{CN}), 1506 m-sh, 1458w, 1434w, 1421w, 1381w, 1360w, 1341w, 1275w, 1247w, 1211w, 1179w, 1134w, 1075 s-sh, 1049 s-br, 1033 s (ν_{BF_4}), 1014 s-sh, 963w, 935w, 865w, 850w, 825w, 808 m, 745 s, 707 m, 657 m. IR (CH₂Cl₂): $\tilde{\nu}/\text{cm}^{-1}$ = 2021 s (ν_{CO}), 1989w (ν_{CO}), 1836 m ($\nu_{\mu\text{-CO}}$), 1538w (ν_{CN}). IR (MeCN): $\tilde{\nu}/\text{cm}^{-1}$ = 2023 s (ν_{CO}), 1990w (ν_{CO}), 1837 m ($\nu_{\mu\text{-CO}}$), 1537w (ν_{CN}). ¹H NMR ([D₆]acetone): δ/ppm = 8.7–8.3 (br, 1H, C4-H/C12-H), 8.30 (d, ³J_{HH} = 8.6 Hz, 1H, C5-H), 8.16–8.09 (m, 2H, C7-H + C10-H), 8.1–7.7 (br, 1H, C4-H/C12-H), 7.75–7.70 (m, 2H, C8-H + C9-H), 5.68 (s, 5H, Cp), 5.19 (q, ³J_{HH} = 7.0 Hz, 2H, C1-H), 4.87 (s, 5H, Cp), 1.51 (t, ³J_{HH} = 7.2 Hz, 3H, C2-H). No changes were observed in the ¹H spectrum after 14 h at room temperature. ¹³C{¹H} ([D₆]acetone): δ/ppm = 325.2 (CN), 255.2 (μ-CO); 210.1, 209.8 (CO); 146.1 (C3); 134.3, 133.9 (C6 + C11); 131.4 (C5); 129.5, 129.0 (C7 + C10); 128.8, 128.6 (C8 + C9); 126.3, 125.1 (C4 + C12); 91.7, 91.2 (Cp); 66.8 (C1), 14.4 (C2). ¹⁹F{¹H} NMR ([D₆]acetone): δ/ppm = –151.0 (¹⁰BF₄), –151.1 (¹¹BF₄). ¹H NMR (CDCl₃): δ/ppm = 8.5–7.8 (br, 4H), 7.70–7.60 (m, 2H), 7.60–7.48 (m-br, 1H), 5.44 (s, 5H), 5.20–5.05 (s-br, 1H), 4.95 (td, *J* = 14.5, 7.3 Hz, 1H), 4.65 (s, 5H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C{¹H} NMR (CDCl₃): δ/ppm = 323.2 (br), 254.9, 209.2 (br), 208.4, ca. 145 (br); 133 (br), 132.9 (br); 130.1 (m), 128.1, 127.9, 126–125 (m-br), 124.0, 120.5, 117.1, 90.6, 90.3, 66 (br), 14.0. ¹⁹F{¹H} NMR (CDCl₃): δ/ppm = –150.9, –151.0. The *cis* orientation of the Cp ligands in **[4G]BF₄** was ascertained by ¹H NOE experiment in CDCl₃. Thus, irradiation of one Cp resonance (δ_{H} 5.44 or 4.65 ppm) evidenced a NOE interaction with the other.


[Fe₂Cp₂(CO)₂(μ-CO){μ-CNBr₂}]X, [5H]X (X = Br, CF₃SO₃)


[5H]Br. In a 100 mL Schlenk tube under N₂, benzyl bromide (1.0 mL, 8.4 mmol) was added dropwise to a dark red solution of **1H** (1.58 mmol) in anhydrous MeCN (50 mL) under vigorous stirring at 60 °C. The mixture was stirred at reflux for 1.5 h and conversion was checked by IR (MeCN). Next, the dark red solution was moved on top of an alumina column (*h* 6.5, *d* 5.5 cm). Impurities were eluted with neat CH₂Cl₂, THF and MeCN, then a red band containing the title product was eluted with MeCN/MeOH (10:1, *v/v*). Volatiles were removed under vacuum (40 °C), affording a red solid. Yield: 892 mg, 92%. Compound **[5H]Br** is soluble in CH₂Cl₂, CHCl₃, THF, *i*PrOH, poorly soluble in toluene, EtOAc, insoluble in Et₂O. IR (CH₂Cl₂): $\tilde{\nu}/\text{cm}^{-1}$ = 2020s (ν_{CO}), 1988w (ν_{CO}), 1837 m ($\nu_{\mu\text{-CO}}$), 1550w (ν_{CN}), 1534w. ¹H NMR (CDCl₃): δ/ppm = 7.48 (t, ³J_{HH} = 7.4 Hz, 4H, C4-H), 7.40 (t, ³J_{HH} = 7.3 Hz, 2H, C5-H), 7.30–7.26 (m, 4H, C3-H), 5.69 (d, ²J_{HH} = 14.7 Hz, 2H, C1-H), 5.56 (s, 10H, Cp), 5.52 (d, ²J_{HH} = 14.7 Hz, 2H, C1-H).

[5H]CF₃SO₃. In a 50 mL round bottom flask, a solution of Ag(CF₃SO₃) (440 mg, 1.71 mmol) in MeCN (5 mL) was added to a dark red solution of **[5H]I** (1045 mg, 1.70 mmol) in MeCN (40 mL) at 0 °C. The mixture was stirred at 0 °C for 1.5 h while maintaining the system under protection from the light. The resulting suspension (dark red solution + pale yellow AgBr precipitate) was filtered over celite and the filtrate solution was dried under vacuum. The residue was treated with hexane (10 mL) then Et₂O (50 mL) and settled aside for 30 min. Therefore, the solution was discarded and the washing procedure was repeated (x 2). The resulting red solid was dried under vacuum (40 °C) and stored under N₂ (slightly hygroscopic).

Yield: 1076 mg, 93%. Compound [5H]CF₃SO₃ is soluble in MeCN, acetone, MeOH, CH₂Cl₂, poorly soluble in Et₂O, toluene, water and insoluble in hexane. Anal. calcd. for C₂₉H₂₄F₃Fe₂NO₆S: C 50.98, H, 3.54, N, 2.05; found: C 50.59, H, 3.58, N, 2.26. IR (solid state): ν /cm⁻¹ = 3106w, 3070–3230w, 2166w, 2013 s (ν_{CO}), 1985 s-sh (ν_{CO}), 1827 s ($\nu_{\mu\text{-CO}}$), 1588w, 1549 m (ν_{CN}), 1533 m, 1497w, 1454w, 1433w, 1420w, 1352w, 1260s (ν_{SO_3}), 1223 s-sh (ν_{SO_3}), 1153 s (ν_{SO_3}), 1096w, 1079w, 1029 s, 858 m, 767 s, 737 m-sh, 698 s. IR (CH₂Cl₂): ν /cm⁻¹ = 2023 s (ν_{CO}), 1991 m (ν_{CO}), 1840 m ($\nu_{\mu\text{-CO}}$), 1550w (ν_{CN}), 1534w. IR (MeCN): ν /cm⁻¹ = 2023 s (ν_{CO}), 1990w (ν_{CO}), 1839 m ($\nu_{\mu\text{-CO}}$), 1552w (ν_{CN}), 1538w. ¹H NMR (CDCl₃): δ /ppm = 7.50–7.44 (m, 4H, C4-H), 7.44–7.39 (m, 2H, C5-H), 7.20 (d, ³J_{HH} = 7.3 Hz, 4H, C3-H), 5.66 (d, ²J_{HH} = 14.6 Hz, 2H, C1-H), 5.50 (d, ²J_{HH} = 14.7 Hz, 2H, C1-H'), 5.40 (s, 10H, Cp). No changes were observed in the ¹H spectrum after 2 days at room temperature. ¹³C{¹H} NMR (CDCl₃): δ /ppm = 324.4 (CN), 253.7 (μ -CO), 208.2 (CO), 132.1 (C2), 129.9 (C4), 129.4 (C5), 127.8 (C3), 121.1 (¹J_{CF} = 313 Hz, CF₃), 90.6 (Cp), 68.9 (C1). ¹⁹F{¹H} NMR (CDCl₃): δ /ppm = -78.1 ppm.

[Fe₂Cp₂Cl(CO)(μ -CO){ μ -CNMe(C₆H₁₁)}], 6



In a 25 mL Schlenk tube under N₂, a red suspension of [2C]CF₃SO₃ (103 mg, 0.172), Me₃NO·2H₂O (35 mg, 0.32 mmol) and LiCl (23 mg, 0.54 mmol) in acetone (8 mL) was stirred at reflux for 5 h. Conversion was checked by IR (acetone) then volatiles were

removed under vacuum. The brown residue was suspended in CH₂Cl₂ and moved on top of an alumina column (*h* 2.5, *d* 4.3 cm), under N₂. Impurities were eluted with CH₂Cl₂ then a brown band containing the title product was eluted with THF. The eluate was dried under vacuum and the residue was suspended in hexane. The suspension was filtered; the resulting brown solid was washed with hexane and dried under vacuum (40 °C). Yield: 55 mg, 70%. A related one-pot reaction with [2C]CF₃SO₃/Me₃NO·2H₂O (1.6 equiv)/NaCl (3.6 equiv) in deaerated MeOH (8 mL) at 40 °C overnight gave **6** in 43% yield. A two-step procedure comprising the [2C]CF₃SO₃/Me₃NO·2H₂O (1 equiv) reaction in MeCN at room temperature followed by LiCl (3.0 equiv) in refluxing acetone for 3 h gave **6** in 54% yield. Compound **6** is soluble in CH₂Cl₂, CHCl₃, scarcely soluble in MeOH, insoluble in Et₂O and hydrocarbons. Crystals of **6** for X-ray analysis were obtained from a CHCl₃ solution layered with pentane and settled aside at -20 °C. IR (CH₂Cl₂): ν /cm⁻¹ = 1977 s (ν_{CO}), 1798 s ($\nu_{\mu\text{-CO}}$), 1537 m (ν_{CN}). IR (MeCN): ν /cm⁻¹ = 1971 s (ν_{CO}), 1795 m ($\nu_{\mu\text{-CO}}$), 1539w (ν_{CN}). IR (solid state): ν /cm⁻¹ = 3104w, 3070w, 1939 s (ν_{CO}), 1782 s ($\nu_{\mu\text{-CO}}$), 1558w-sh, 1536 s (ν_{CN}), 1456w, 1447w, 1419w, 1394 m, 1360w, 1346w, 1317w, 1251w, 1182w, 1153w, 1116w, 1062 m, 1016w, 1001w, 993 m, 857w-sh, 838 m, 814 m, 800s, 757 s. ¹H/¹³C NMR: mixture of isomers in 3:2 ratio (¹H CDCl₃). Signals attributable to the minor isomer are italicized. ¹H NMR (CDCl₃): δ /ppm = 6.09, 5.01 (tt, ³J_{HH} = 12.0, 3.2 Hz, 1H, C2-H); 4.72, 4.70 (s, 5H, Cp); 4.64, 4.62 (s, 5H, Cp'); 4.53, 4.05 (s, 3H, C1-H); 2.59, 2.37 (d, *J* = 12.0 Hz, 1H, C3-H); 2.28–2.06, 1.98–1.69, 1.42–1.24 (m, 9H, C3-H' + C4-H + C5-H). No change in the ¹H NMR spectrum was observed after 14 h at room temperature. ¹³C{¹H} NMR (CDCl₃): δ /ppm = 334.8, 334.5 (CN); 268.1, 267.5 (μ -CO); 212.5, 211.9 (CO); 86.8, 86.6 (Cp); 86.4, 86.3 (Cp'); 76.6, 75.4 (C2-H); 44.4, 43.6 (C1-H), 32.5, 32.1 (C3-H); 32.3, 30.6, 26.3, 26.2, 26.0, 25.6, 25.6, 25.5 (C3'-H + C4-H + C5-H).

X-ray crystallography

Crystal data and collection details for [2A]CF₃SO₃, [2C]Cl·2.34H₂O, [2C]CF₃SO₃, [2D]CF₃SO₃ and **6** are reported in Table 7. Data were

Table 7. Crystal data and measurement details for [2A]CF₃SO₃, [2C]Cl·2.34H₂O, [2C]CF₃SO₃, [2D]CF₃SO₃ and **6**.

	[2C]Cl·2.34H ₂ O	[2C]CF ₃ SO ₃	[2A]CF ₃ SO ₃	[2D]CF ₃ SO ₃	6
Formula	C ₂₁ H ₂₄ ClFe ₂ NO _{5.34}	C ₂₂ H ₂₄ F ₃ Fe ₂ NO ₆ S	C ₂₄ H ₁₉ F ₃ Fe ₂ N ₂ O ₆ S	C ₂₃₂ H ₂₀ F ₃ Fe ₂ NO ₇ S	C ₂₀ H ₂₄ ClFe ₂ NO ₂
FW	523.04	599.18	632.17	623.16	457.55
T, K	100(2)	100(2)	100(2)	100(2)	100(2)
λ , Å	0.71073	0.71073	0.71073	0.71073	0.71073
Crystal system	triclinic	orthorhombic	monoclinic	monoclinic	monoclinic
Space group	<i>P</i> $\bar{1}$	<i>Pna</i> 2 ₁	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> 2 ₁ / <i>n</i>
<i>a</i> , Å	10.8828(6)	21.468(3)	9.3327(8)	9.9264(9)	6.9490(15)
<i>b</i> , Å	15.1007(8)	11.9137(18)	20.1635(17)	14.5214(12)	22.695(5)
<i>c</i> , Å	15.1537(8)	8.9585(16)	12.8705(10)	17.1821(15)	12.227(2)
α , °	77.457(3)	90	90	90	90
β , °	87.276(3)	90	100.145(4)	102.180(3)	97.775(6)
γ , °	69.367(3)	90	90	90	90
Cell Volume, Å ³	2273.8(2)	2291.3(6)	2384.1(3)	2421.0(4)	1910.7(7)
Z	4	4	4	4	4
<i>D</i> _c , g cm ⁻³	1.528	1.737	1.761	1.710	1.591
μ , mm ⁻¹	1.426	1.423	1.374	1.353	1.672
F(000)	1075	1224	1280	1264	944
Crystal size, mm	0.21 × 0.18 × 0.15	0.22 × 0.19 × 0.12	0.21 × 0.16 × 0.13	0.24 × 0.21 × 0.12	0.22 × 0.16 × 0.13
θ limits, °	1.790–26.000	1.897–25.488	1.898–25.050	1.854–25.097	1.795–23.999
Reflections collected	28243	20143	38770	54774	22519
Independent reflections	8885 [<i>R</i> _{int} = 0.0496]	4040 [<i>R</i> _{int} = 0.1419]	4173 [<i>R</i> _{int} = 0.0569]	4267 [<i>R</i> _{int} = 0.0875]	2933 [<i>R</i> _{int} = 0.1406]
Data/restraints /parameters	8885/0/567	4040/193/318	4173/1/347	4267/0/336	2933/264/235
Goodness on fit on F ²	1.246	1.278	1.243	1.181	1.238
<i>R</i> ₁ (<i>I</i> > 2 σ (<i>I</i>))	0.0871	0.0939	0.0729	0.0614	0.1692
<i>wR</i> ₂ (all data)	0.2056	0.1657	0.1521	0.1426	0.4021
Largest diff. peak and hole, e Å ⁻³	0.901/−0.810	1.090/−0.698	0.905/−0.752	1.346/−0.936	2.986/−2.257

recorded on a Bruker APEX II diffractometer equipped with a PHOTON2 detector using $\text{MoK}\alpha$ radiation. The structures were solved by direct methods and refined by full-matrix least-squares based on all data using F^2 .^[49] Hydrogen atoms were fixed at calculated positions and refined using a riding model, except H(2) in $[\mathbf{2A}]\text{CF}_3\text{SO}_3$ which was located in the Fourier map and refined isotropically using the 1.2-fold U_{iso} of the parent N(2) atom. The H_2O molecules of $[\mathbf{2C}]\text{Cl}\cdot 2.34\text{H}_2\text{O}$ are disordered and it was not possible to locate the hydrogen atoms. All non-hydrogen atoms were refined with anisotropic displacement parameters. The crystals of **6** display a low quality, allowing the full determination of the overall connectivity and geometry of the complex, while the bonding parameters cannot be discussed in detail.

Computational studies

All geometries were optimized with ORCA 4.0.1.2,^[50] using the B97 functional in conjunction with a triple- ζ quality basis set (def2-TZVP). The dispersion corrections were introduced using the Grimme D3-parametrized correction and the Becke–Johnson damping to the DFT energy.^[51] Most of the structures were confirmed to be local energy minima (no imaginary frequencies), but in some case a small, unavoidable negative frequency relative to the Cp rotation around the M–Cp axis was observed. The solvent was considered through the continuum-like polarizable continuum model (C-PCM, dichloromethane).

Behaviour in aqueous media

Solubility in water. A suspension of the selected Fe compound (3–5 mg) in a D_2O solution (0.7 mL) containing Me_2SO_2 as internal standard^[52] ($3.36\cdot 10^{-3}$ M) was vigorously stirred at 21 °C for 10 h. The resulting saturated solution was filtered over celite, transferred into an NMR tube and analysed by ^1H NMR spectroscopy (delay time = 3 s; number of scans = 20). For the most soluble compounds ($S \geq 0.05$ M), a saturated solution was prepared in a smaller volume of $\text{D}_2\text{O}/\text{Me}_2\text{SO}_2$ (0.2–0.3 mL), then filtered and diluted with pure D_2O . The concentration (solubility) was calculated by the relative integral with respect to Me_2SO_2 ($\delta/\text{ppm} = 3.14$ (s, 6H)). Results are compiled in Table 3.

Octanol/water partition coefficients ($\log P_{ow}$). Partition coefficients (P_{ow} ; IUPAC: K_D partition constant^[53]), defined as $P_{ow} = c_{org}/c_{aq}$, where c_{org} and c_{aq} are molar concentrations of the selected compound in the organic and aqueous phase, respectively, were determined by the shake-flask method and UV/Vis measurements.^[16a,54] Deionized water and octan-1-ol were vigorously stirred for 24 h, to enable saturation of both phases, then separated by centrifugation. A stock solution of the selected Fe compound (ca. 2 mg) was prepared by first adding acetone (50 μL , to help solubilization), followed by water-saturated octanol (2.5 mL). The solution was diluted with water-saturated octanol (ca. 1:3 v/v ratio, $c_{\text{Fe}_2} \approx 10^{-4}$ M, so that $1.5 \leq A \leq 2.0$ at λ_{max}) and its UV/Vis spectrum was recorded (A_{org}^0). An aliquot of the solution ($V_{org} = 1.2$ mL) was transferred into a test tube and octanol-saturated water ($V_{org} = V_{aq} = 1.2$ mL) was added. The mixture was vigorously stirred for 30 min at 21 °C then centrifuged (RCF 805, 5 min; Hettich EBA 8G). The UV/Vis spectrum of the organic phase was recorded (A_{org}^f) and the partition coefficient was calculated as $P_{ow} = A_{org}^f / (A_{org}^0 - A_{org}^f)$ where A_{org}^0 and A_{org}^f are the absorbance in the organic phase before and after partition with the aqueous phase, respectively.^[53] For $[\mathbf{2B}]\text{BF}_4$, $[\mathbf{2C}]\text{Cl}$ and $[\mathbf{3F}]\text{CF}_3\text{SO}_3$ an inverse procedure was followed, starting from a solution of the compound in octanol-saturated water. The partition coefficient was calculated as $P_{ow} = (A_{aq}^0 - A_{aq}^f) / A_{aq}^f$ where A_{aq}^0 and A_{aq}^f are the absorbance in the aqueous phase before and after partition with the organic phase, respectively. The wavelength of the

maximum absorption of each compound (320–390 nm range) was used for UV/Vis quantitation. The procedure was repeated three times for each sample (from the same stock solution); results are given as mean \pm standard deviation (Table 3). Naphthoquinone was used as a reference compound ($\log P = 1.8 \pm 0.2$; literature.^[55] 1.71).

Stability in water (D_2O) and cell culture medium. The procedures are described in the Supporting Information, and data are collected in Table S3.

Carbon monoxide release. A stock solution was prepared by dissolving the selected Fe compound (ca. 10 mg) in MeOH (0.50 mL) then diluting with H_2O up to 10.0 mL total volume (5% v/v MeOH). Next, 3.20 mL of the solution (n_{Fe} ca. $6\cdot 10^{-3}$ mmol) and a 7x2 mm stir bar were transferred into a 4-mL screw top vial (1.72 mL neat gas phase volume). The mixture was sealed with a screw cap with a PTFE/silicone septum and heated at 37 °C for 24 h under stirring. Afterwards, the headspace was sampled with a gas tight microsyringe (250 μL) and analysed by GC-TCD. Therefore, the vial was vented, sealed and heated for further 24 h, and GC-TCD analysis was repeated. The amount of released CO (v_{CO} , mmol) was calculated based on a calibration curve obtained from analyses of known air/CO mixtures (1–10% v/v), and the number of equivalents released over a 24 h period refers to the initial amount of compound ($\text{eq}_{\text{CO}} = n_{\text{CO}}/n_{\text{Fe}}$). The residual amount of starting diiron complex after 48 h was calculated by assuming the release of 3 equivalents of CO per mole and the total amount of CO released. The procedure was repeated three times for each sample (from the same stock solution); results are given as mean \pm standard deviation (Table S4).

Reactivity with model protein

Lysozyme from chicken egg white ($M = 14\,300$ Da, 62971 Sigma-Aldrich) was stored at 4 °C as received. A stock solution was prepared by dissolving the powder protein (125 μM) and NH_4OAc ($1.25\cdot 10^{-2}$ M)^[56] in HPLC water and was immediately used. Stock solutions of diiron complexes ($c_{\text{Fe}_2} = 1\cdot 10^{-3}$ M) were prepared by dissolving the selected compound in DMSO (0.25 mL) or MeOH (0.7 mL; used only for $[\mathbf{4G}]\text{BF}_4$), then diluting with HPLC water up to 5.0 mL total volume. Next, aliquots of the Fe (0.50 mL) and lysozyme (2.0 mL) stock solutions were mixed and the final solution (Fe_2 200 μM , lysozyme 100 μM , NH_4OAc 10 mM; 1% DMSO) was kept at 37 °C for 24 h. The resulting suspensions were centrifuged (RCF 805, 5 min; Hettich EBA 8G) to separate the orange-brown precipitate. A blank solution (lysozyme only) was prepared and treated by the same procedure. Next, samples were diluted 1:20 (v/v) with a water/MeCN (1:1, v/v) solution containing 1% formic acid and analysed by HPLC-MS and flow injection MS. For HPLC analyses, elution was conducted with a MeCN/water linear gradient (90:10 to 5:95 v/v over 60 min), containing 0.05% trifluoroacetic acid. The following compounds were identified by their MS pattern: $[\mathbf{2A}]^+$ ($t_R = 18.0$ min), $[\mathbf{2B}]^+$ ($t_R = 13.8$ min), $[\mathbf{2C}]^+$ ($t_R = 18.8$ min), $[\mathbf{2D}]^+$ ($t_R = 17.0$ min), $[\mathbf{2E}]^+$ ($t_R = 18.3$ min), $[\mathbf{2F}]^+$ ($t_R = 9.7$ min), $[\mathbf{3F}]^+$ ($t_R = 13.1$ min), $[\mathbf{4G}]^+$ ($t_R = 23.0$ min), $[\mathbf{5H}]^+$ ($t_R = 24.3$ min), lysozyme- CH_3 ($t_R = 21.0$ min), lysozyme ($t_R = 21.6$ min). In all cases, the starting organometallic cation was identified as the major Fe-containing compound in solution. Protein peaks pattern were obtained following peak reconstruction. Peak integrals for lysozyme and methyl lysozyme were calculated from the extracted ion chromatograms from the flow injection MS analysis (Table 4). MS patterns are displayed in Figures S33–S41.

Biological studies

Compounds [2B]BF₄, [2C]CF₃SO₃, [2D]CF₃SO₃ and [3F]CF₃SO₃ were dissolved in water while the other compounds were dissolved in the minimum DMSO amount prior to cell culture testing. A calculated amount of the stock drug DMSO solution was added to the cell culture media to reach a final maximum DMSO concentration of 0.5%, which had no effects on cell viability.

Cisplatin was dissolved in 0.9% sodium chloride solution. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], cisplatin and ImmunoPure *p*-nitrophenyl phosphate (APH) were obtained from Sigma-Aldrich.

Cell cultures. Human colon (HCT-15), pancreatic (PSN-1) and breast (MCF-7) carcinoma cell lines along with human melanoma cells (A375) were obtained from American Type Culture Collection (ATCC, Rockville, MD). Embryonic kidney HEK293 cells were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK). Human ovarian 2008 cancer cells were kindly provided by Prof. G. Marverti (Dept. of Biomedical Science of Modena University, Italy). MCF-7 ADR cells were kindly provided by Prof. N. Colabufo (Dept. Pharmacy, University of Bari, Italy). Cell lines were maintained in the logarithmic phase at 37 °C in a 5% CO₂ atmosphere using the following culture media containing 10% fetal calf serum (Euroclone, Milan, Italy), antibiotics (50 units/mL penicillin and 50 µg/mL streptomycin) and 2 mM L-glutamine: i) RPMI-1640 medium (Euroclone, Milan, Italy) for PSN-1, 2008, HCT-15, MCF-7 and MCF-7 ADR cells; ii) DMEM for A375 and HEK293 cells.

Spheroid cultures. Spheroid cultures were obtained by seeding 2.5 × 10³ cells/well in round bottom non-tissue culture treated 96 well-plate (Greiner Bio-one, Kremsmünster, Austria) in phenol red free RPMI-1640 medium (Sigma Chemical Co.), containing 10% FCS and supplemented with 20% methyl cellulose stock solution.

MTT assay. The growth inhibitory effect towards tumour cells was evaluated by means of MTT assay as previously described.^[57] Briefly, 3–8 × 10³ cells/well, dependent upon the growth characteristics of the cell line, were seeded in 96-well microplates in growth medium (100 µL). After 24 h, the medium was removed and replaced with a fresh one containing the compound to be studied at the appropriate concentration. Triplicate cultures were established for each treatment. After 24 or 72 h, each well was treated with 10 µL of a 5 mg/mL MTT saline solution, and following 5 h of incubation, 100 µL of a sodium dodecyl sulfate (SDS) solution in HCl 0.01 M were added. After an overnight incubation, cell growth inhibition was detected by measuring the absorbance of each well at 570 nm using a Bio-Rad 680 microplate reader. Mean absorbance for each drug dose was expressed as a percentage of the control untreated well absorbance and plotted against drug concentration. IC₅₀ values, the drug concentrations that reduce the mean absorbance at 570 nm to 50% of those in the untreated control wells, were calculated by the four-parameter logistic (4-PL) model. Evaluation was based on means from at least four independent experiments.

Acid phosphatase (APH) assay. An APH modified assay was used for determining cell viability in 3D spheroids, as previously described.^[58] IC₅₀ values were calculated with a four-parameter logistic (4-PL) model. All the values are the means ± SD of not less than four independent experiments.

Mitochondrial membrane potential (ΔΨ). The ΔΨ was assayed using the Mito-ID® Membrane Potential Kit according to the manufacturer's instructions (Enzo Life Sciences, Farmingdale, NY) as previously described.^[59] Briefly, PSN-1 cells (8 × 10³ per well) were seeded in 96-well plates; after 24 h, cells were washed with PBS and loaded with Mito-ID detection reagent for 30 min at 37 °C in the dark. Afterwards, cells were incubated with increasing concentra-

tions of tested complexes. Fluorescence intensity was estimated using a VICTOR X3 (PerkinElmer, USA) plate reader at λ_{ex} = 490 and λ_{em} = 590 nm. Antimycin (3 µM) was used as positive control.

ROS production. The production of ROS was measured in PSN-1 cells (10⁴ per well) grown for 24 h in a 96-well plate in RPMI medium without phenol red (Merck). Cells were then washed with PBS and loaded with 10 µM 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H₂DCFDA; Molecular Probes-Invitrogen) for 25 min, in the dark. Afterwards, cells were washed with PBS and incubated with increasing concentrations of tested compounds. Fluorescence increase was estimated by using λ_{ex} = 485 nm and λ_{em} = 527 nm in a VICTOR X3 (PerkinElmer) plate reader. Antimycin (3 µM, Merck), a potent inhibitor of Complex III in the electron transport chain, was used as positive control.

Intracellular CO release. PSN-1 cell (1 × 10⁴) were seeded in 96-well plates. After 24 h, cells were treated with 20 µM of tested complexes or CORM-401 (Merck) for 15 min at 37 °C and followed by 30 min incubation with a fluorescent probe BioTracker Carbon Monoxide Probe 1 Live Cell Dye® (Merck). The intracellular fluorescence, indicative of CO accumulation in cells, was quantified using a VICTOR X3 (PerkinElmer) plate reader.

Cellular uptake. PSN-1 and HEK293 cells (3 × 10⁶) were seeded in 75 cm² flasks in growth medium (20 mL). After overnight incubation, the medium was replaced and the cells were treated with tested compounds for 24 h. Cell monolayers were washed twice with cold PBS, harvested and counted. Samples were then subjected to three freezing/thawing cycles at –80 °C, and then vigorously vortexed. The samples were treated with highly pure nitric acid (Fe: ≤ 0.01 µg kg⁻¹, TraceSELECT® Ultra, Sigma) and transferred into a microwave Teflon vessel. Subsequently, samples were submitted to standard procedures using a speed wave MWS-3 Berghof instrument (Eningen, Germany). After cooling, each mineralized sample was analysed for iron using a Varian AA Duo graphite furnace atomic absorption spectrometer (Varian) at the wavelength of 248.3 nm. The calibration curve was obtained using known concentrations of standard solutions purchased from Sigma Chemical Co.

Statistical analysis. All values are the means ± SD of no less than three measurements starting from three different cell cultures. Multiple comparisons were made by ANOVA followed by the Tukey-Kramer multiple comparison test (**p* < 0.05, ***p* < 0.01), using GraphPad software.

Supporting Information

IR and NMR spectra of products and comparison of selected spectroscopic data; DTF optimized structures; stability studies in water and cell culture media; carbon monoxide release studies; IC₅₀ values after 24 h of incubation; MS spectra from lysozyme interaction experiments. Deposition numbers 2045779 (for [2A] CF₃SO₃), 2045778 (for [2C]CF₃SO₃), 2045777 (for [2C]Cl), 2045780 (for [2D]CF₃SO₃) and 2045781 (for 6) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.

Acknowledgements

We gratefully thank the Universities of Pisa (Fondi di Ateneo 2020 and PRA_2020_39) and Padova (DOR 2019) for financial support, Dr. Beatrice Campanella (ICCOM – CNR, Pisa, Italy) for Raman analysis and Dr. Andrea Raffaelli (ICF – CNR, Pisa, Italy) for MS and HPLC-MS analyses.

Conflict of Interest

The authors declare no conflict of interest.

Keywords: bioinorganic chemistry · CO release; cytotoxicity · diiron complexes · 3D cancer cell models

- [1] a) E. Boros, P. J. Dyson, G. Gasser, *Chem.* **2020**, *6*, 41–60; b) K. L. Haas, K. J. Franz, *Chem. Rev.* **2009**, *109*, 4921–4960; c) E. J. Anthony, E. M. Bolitho, H. E. Bridgewater, O. W. L. Carter, J. M. Donnelly, C. Imberti, E. C. Lant, F. Lermyte, R. J. Needham, M. Palau, P. J. Sadler, H. Shi, F.-X. Wang, W.-Y. Zhang, Z. Zhang, *Chem. Sci.* **2020**, *11*, 12888–12917.
- [2] a) M. G. Apps, E. H. Y. Choi, N. J. Wheate, *Endocrine-Related Cancer* **2015**, *22*, R219–R233; b) D. Gibson, *Dalton Trans.* **2009**, 10681–10689.
- [3] a) R. Oun, Y. E. Moussa, N. J. Wheate, *Dalton Trans.* **2018**, *47*, 6645–6653; b) Z. H. Siddik, *Oncogene* **2003**, *22*, 7265–7279; c) S. Dasari, P. B. Tchounwou, *Eur. J. Pharmacol.* **2014**, *740*, 364–378.
- [4] Selected recent references: a) B. S. Murray, P. J. Dyson, *Curr. Opin. Chem. Biol.* **2020**, *56*, 28–34; b) P. Štarha, Z. Trávníček, *Coord. Chem. Rev.* **2019**, *395*, 130–145; c) I. Bratsos, T. Gianferrara, E. Alessio, C. G. Hartinger, M. A. Jakupec, B. K. Keppler, *Ruthenium and Other Non-Platinum Anticancer Compounds, in Bioinorganic Medicinal Chemistry*, Ed. E. Alessio, Wiley-VCH, Weinheim, **2011**, 151–174; d) P. Zhang, P. J. Sadler, *J. Organomet. Chem.* **2017**, *839*, 5–14.
- [5] a) W. Kaim, B. Schwederski, A. Klein, *Bioinorganic Chemistry: Inorganic Elements in the Chemistry of Life*, 2nd ed., Wiley **2013**; b) M. A. Zoroddu, J. Aseath, G. Crisponi, S. Medici, M. Peana, V. M. Nurchi, *J. Inorg. Biochem.* **2019**, *195*, 120–129.
- [6] U. Basu, M. Roy, A. R. Chakravarty, *Coord. Chem. Rev.* **2020**, *417*, 213339.
- [7] a) A. A. Simenel, E. A. Morozova, L. V. Snegur, S. I. Zykova, V. V. Kachala, L. A. Ostrovskaya, N. V. Bluchterova, M. M. Fomina, *Appl. Organomet. Chem.* **2009**, *23*, 219–224; b) L. V. Snegur, Y. S. Nekrasov, N. S. Sergeeva, Z. V. Zhilina, V. V. Gumenyuk, Z. A. Starikova, A. A. Simenel, N. B. Morozova, I. K. Sviridova, V. Babin, *Appl. Organomet. Chem.* **2008**, *22*, 139–147.
- [8] a) R. Wang, H. Chen, W. Yan, M. Zheng, T. Zhang, Y. Zhang, *Eur. J. Med. Chem.* **2020**, *190*, 112109; b) M. Patra, G. Gasser, *Nat. Chem. Rev.* **2017**, *1*, 0066; c) G. Jaouen, A. Vessières, S. Top, *Chem. Soc. Rev.* **2015**, *44*, 8802–8817; d) S. Peter, B. A. Aderibigbe, *Molecules* **2019**, *24*, 3604.
- [9] a) Y. Wang, P. M. Dansette, P. Pigeon, S. Top, M. J. McGlinchey, D. Mansuy, G. Jaouen, *Chem. Sci.* **2018**, *9*, 70–78; b) Y. Wang, M.-A. Richard, S. Top, P. M. Dansette, P. Pigeon, A. Vessières, D. Mansuy, G. Jaouen, *Angew. Chem. Int. Ed.* **2016**, *55*, 10431–10434; *Angew. Chem.* **2016**, *128*, 10587–10590.
- [10] a) D. BenYosef, D. Romano, M. Hadiji, P. J. Dyson, B. Blom, *Inorg. Chim. Acta* **2020**, *510*, 119731; b) H. T. Poh, P. C. Ho, W. Y. Fan, *RSC Adv.* **2016**, *6*, 18814–18823; c) A. Pilon, P. Gírio, G. Nogueira, F. Avecilla, H. Adams, J. Lorenzo, M. H. Garcia, A. Valente, *J. Organomet. Chem.* **2017**, *852*, 34–42.
- [11] a) P. R. Florindo, D. M. Pereira, P. M. Borralho, C. M. P. Rodrigues, M. F. M. Piedade, A. C. Fernandes, *J. Med. Chem.* **2015**, *58*, 4339–4347; b) A. Valente, A. M. Santos, L. Côte-Real, M. P. Robalo, V. Moreno, M. Font-Bardia, T. Calvet, J. Lorenzo, M. H. Garcia, *J. Organomet. Chem.* **2014**, *756*, 52–60; c) A. Pilon, A. R. Brás, L. Côte-Real, F. Avecilla, P. J. Costa, A. Preto, M. H. Garcia, A. Valente, *Molecules* **2020**, *25*, 1592; d) A. C. Gonçalves, T. S. Morais, M. P. Robalo, F. Marques, F. Avecilla, C. P. Matos, I. Santos, A. I. Tomaz, M. H. Garcia, *J. Inorg. Biochem.* **2013**, *129*, 1–8.
- [12] X. Jiang, L. Chen, X. Wang, L. Long, Z. Xiao, X. Liu, *Chem. Eur. J.* **2015**, *21*, 13065–13072.
- [13] A. Vessières, Y. Wang, M. J. McGlinchey, G. Jaouen, *Coord. Chem. Rev.* **2021**, *430*, 213658.
- [14] a) O. Buriez, J. M. Heldt, E. Labb, A. Vessières, G. Jaouen, C. Amatore, *Chem. Eur. J.* **2008**, *14*, 8195–8203; b) A. Notaro, G. Gasser, A. Castonguay, *ChemMedChem* **2020**, *15*, 345–348.
- [15] Selected references: a) R. Mazzoni, M. Salmi, V. Zanotti, *Chem. Eur. J.* **2012**, *18*, 10174–10194, and references therein; b) F. Marchetti, *Eur. J. Inorg. Chem.* **2018**, 3987–4003, and references therein; c) M. E. García, D. García-Vivó, A. Ramos, M. A. Ruiz, *Coord. Chem. Rev.* **2017**, *330*, 1–36; d) Y. Chen, L. Liu, Y. Peng, P. Chen, Y. Luo, J. Qu, *J. Am. Chem. Soc.* **2011**, *133*, 1147–1149; e) J. He, C.-L. Deng, Y. Li, Y.-L. Li, Y. Wu, L.-K. Zou, C. Mu, Q. Luo, B. Xie, J. Wei, *Organometallics* **2017**, *36*, 1322–1330.
- [16] a) G. Agonigi, L. Biancalana, M. G. Lupo, M. Montopoli, N. Ferri, S. Zacchini, F. Binacchi, T. Biver, B. Campanella, G. Pampaloni, V. Zanotti, F. Marchetti, *Organometallics* **2020**, *39*, 645–657; b) S. Schoch, L. K. Batchelor, T. Funaioli, G. Ciancaleoni, S. Zacchini, S. Braccini, F. Chiellini, T. Biver, G. Pampaloni, P. J. Dyson, F. Marchetti, *Organometallics* **2020**, *39*, 361–373.
- [17] a) D. Rocco, L. K. Batchelor, G. Agonigi, S. Braccini, F. Chiellini, S. Schoch, T. Biver, T. Funaioli, S. Zacchini, L. Biancalana, M. Ruggeri, G. Pampaloni, P. J. Dyson, F. Marchetti, *Chem. Eur. J.* **2019**, *25*, 14801–14816; b) G. Agonigi, L. K. Batchelor, E. Ferretti, S. Schoch, M. Bortoluzzi, S. Braccini, F. Chiellini, L. Biancalana, S. Zacchini, G. Pampaloni, B. Sarkar, P. J. Dyson, F. Marchetti, *Molecules* **2020**, *25*, 1656.
- [18] R. Maddaly, A. Subramaniyan, H. Balasubramanian, *J. Cell. Biochem.* **2017**, *118*, 2544–2558.
- [19] a) R. Edmondson, J. Jenkins Broglie, A. F. Adcock, L. Yang, *Assay Drug Dev. Technol.* **2014**, *12*, 207–218; b) D. Loessner, K. S. Stok, M. P. Lutolf, D. W. Huttmacher, J. A. Clements, S. C. Rizzi, *Biomaterials* **2010**, *31*, 8494–8506.
- [20] L. Biancalana, G. Ciancaleoni, S. Zacchini, G. Pampaloni, F. Marchetti, *Inorg. Chim. Acta* **2020**, *517*, 120181.
- [21] G. Agonigi, M. Bortoluzzi, F. Marchetti, G. Pampaloni, S. Zacchini, V. Zanotti, *Eur. J. Inorg. Chem.* **2018**, 960–971, and references therein.
- [22] L. Busetto, F. Marchetti, S. Zacchini, V. Zanotti, *Organometallics* **2006**, *25*, 4808–4816.
- [23] S. Willis, A. R. Manning, F. S. Stephens, *J. Chem. Soc. Dalton Trans.* **1980**, 186–191.
- [24] Y. Han, W. Dong, Q. Guo, X. Li, L. Huang, *Eur. J. Med. Chem.* **2020**, *203*, 112506.
- [25] a) P. Finkbeiner, J. P. Hehn, C. Gnam, *J. Med. Chem.* **2020**, *63*, 7081–7107; b) J. B. Rodriguez, C. Gallo-Rodriguez, *ChemMedChem* **2019**, *14*, 190–216.
- [26] A. J. Bridgeman, G. Cavigliasso, L. R. Ireland, J. Rothery, *J. Chem. Soc. Dalton Trans.* **2001**, 2095–2108.
- [27] M. Ennis, R. Kumar, A. R. Manning, J. A. S. Howell, P. Mathur, A. J. Rowan, F. S. Stephens, *J. Chem. Soc. Dalton Trans.* **1981**, 1251–1259.
- [28] V. G. Albano, L. Busetto, F. Marchetti, M. Monari, S. Zacchini, V. Zanotti, *Z. Naturforsch.* **2007**, *62b*, 427–438.
- [29] G. Bistoni, S. Rampino, N. Scafuri, G. Ciancaleoni, D. Zuccaccia, L. Belpassi, F. Tarantelli, *Chem. Sci.* **2016**, *7*, 1174–1184.
- [30] a) M. Knorr, I. Jourdain, A. S. Mohamed, A. Khatyr, S. G. Koller, C. Strohmam, *J. Organomet. Chem.* **2015**, *780*, 70–85; b) M. A. Alvarez, M. E. García, D. García-Vivo, M. A. Ruiz, M. F. Vega, *Organometallics* **2013**, *32*, 4543–4555.
- [31] In both the X-ray structures, the anion strongly interacts with the C–H of the Cp ligands (shortest X·H–C distances 2.797 and 2.165 Å for [2C]Cl and [2C]CF₃SO₃, respectively). Assuming that in low-polar solvents the ion pair structures are preserved, it appears evident that the anion can affect the Cp chemical shifts.
- [32] Related aminocarbyne complexes behave as 1:1 electrolytes in nitromethane ($\mu = 3.46$ D): I. S. Willis, A. R. Manning, F. S. Stephens, *J. Chem. Soc. Dalton Trans.* **1980**, 186–191.
- [33] Stability experiments performed in D₂O/[D₆]DMSO mixtures differ in that formation of [Fe₂Cp₂(CO)(μ-CO){μ-CNMeR}(DMSO)]⁺ is observed, without any precipitate (Scheme S2).
- [34] a) A. Leonidova, P. Anstaett, V. Pierroz, C. Mari, B. Spingler, S. Ferrari, G. Gasser, *Inorg. Chem.* **2015**, *54*, 9740–9748; b) P. Marzenell, H. Hagen, L. Sellner, T. Zenz, R. Grinyte, V. Pavlov, S. Daum, A. Mokhir, *J. Med. Chem.* **2013**, *56*, 6935–6944.
- [35] X. Jiang, Z. Xiao, W. Zhong, X. Liu, *Coord. Chem. Rev.* **2021**, *429*, 213634.
- [36] L. Messori, A. Merlino, *Chem. Commun.* **2017**, *53*, 11622–11633.
- [37] a) W. Ki Paik, D. C. Paik, S. Kim, *Trends Biochem. Sci.* **2007**, *32*, 146–152; b) H. Carlsson, S. M. Rappaport, M. Törnqvist, *High-Throughput Screening* **2019**, *8*, 6; c) H. Carlsson, H. von Stedingk, U. Nilsson, M. Törnqvist, *Chem. Res. Toxicol.* **2014**, *27*, 2062–2070.

- [38] D. V. LaBarbera, B. G. Reid, B. H. Yoo, *Expert Opin. Drug Discovery* **2012**, *7*, 819–830.
- [39] D. Rocco, N. Busto, C. Pérez-Arnaiz, L. Biancalana, S. Zacchini, G. Pampaloni, B. Garcia, F. Marchetti, *Appl. Organomet. Chem.* **2020**, *34*, e5923.
- [40] K. Jomova, S. Baros, M. Valko, *Trans. Met. Chem.* **2012**, *37*, 127–134.
- [41] R. Mazzoni, A. Gabiccini, C. Cesari, V. Zanotti, I. Gualandi, D. Tonelli, *Organometallics* **2015**, *34*, 3228–3235.
- [42] V. Scalcon, M. Salmain, A. Folda, S. Top, P. Pigeon, L. H. Z. Shirley, G. Jaouen, A. Bindoli, A. Vessières, M. P. Rigobello, *Metallomics* **2017**, *9*, 949–959.
- [43] a) E. S. Arnér, M. Björnstedt, A. Holmgren, *J. Biol. Chem.* **1995**, *270*, 3479–3482; b) J. Nordberg, L. Zhong, A. Holmgren, E. S. Arnér, *J. Biol. Chem.* **1998**, *273*, 10835–10842.
- [44] S. Keller, Y. C. Ong, Y. Lin, K. Cariou, G. Gasser, *J. Organomet. Chem.* **2020**, *906*, 121059.
- [45] G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman, B. M. Stoltz, J. E. Bercaw, K. I. Goldberg, *Organometallics* **2010**, *29*, 2176–2179.
- [46] R. K. Harris, E. D. Becker, S. M. Cabral De Menezes, R. Goodfellow, P. Granger, *Pure Appl. Chem.* **2001**, *73*, 1795–1818.
- [47] W. Willker, D. Leibfritz, R. Kerssebaum, W. Bermel, *Magn. Reson. Chem.* **1993**, *31*, 287–292.
- [48] F. Menges, “Spectragryph—optical spectroscopy software”, version 1.2.9, © 2018, <http://www.effemm2.de/spectragryph>.
- [49] G. M. Sheldrick, *Acta Crystallogr. Sect. C* **2015**, *71*, 3–8.
- [50] F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.* **2017**, *8*, e1327.
- [51] S. Grimme, J. Antony, S. Ehrlich, H. Krieg, *J. Chem. Phys.* **2010**, *132*, 154104.
- [52] T. Rundlöf, M. Mathiasson, S. Bekiroglu, B. Hakkarainen, T. Bowden, T. Arvidsson, *J. Pharm. Biomed. Anal.* **2010**, *52*, 645–651.
- [53] N. M. Rice, H. M. N. H. Irving, M. A. Leonard, *Pure Appl. Chem.* **1993**, *65*, 2373–2396.
- [54] a) *OECD Guidelines for Testing of Chemicals, Vol. 107*, OECD, Paris, **1995**; b) J. C. Dearden, G. M. Bresnen, *Quant. Struct.-Act. Relat.* **1988**, *7*, 133–144.
- [55] D. J. Currie, C. E. Lough, R. F. Silver, H. L. Holmes, *Can. J. Chem.* **1966**, *44*, 1035–1043.
- [56] L. Konermann, *J. Am. Soc. Mass Spectrom.* **2017**, *28*, 1827–1835.
- [57] M. Pellei, V. Gandin, L. Marchiò, C. Marzano, L. Bagnarelli, C. Santini, *Molecules* **2019**, *24*, 1761.
- [58] V. Gandin, C. Ceresa, G. Esposito, S. Indraccolo, M. Porchia, F. Tisato, C. Santini, M. Pellei, C. Marzano, *Sci. Rep.* **2017**, *7*, 13936.
- [59] K. Dammak, M. Porchia, M. De Franco, M. Zancato, H. Naili, V. Gandin, C. Marzano, *Molecules* **2020**, *25*, 5484.

Manuscript received: March 23, 2021

Version of record online: June 9, 2021